## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

## 1.SECTION A - SOLICTTATION/CONTRACT FORM

The total cost of this contract was decreased by $\$ 991,510.00$ from $\$ 1,814,614,507.00$ to $\$ 1,813,622,997.00$.

## 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

## SUBCLIN 0017AA

The target cost has decreased by $\$$ from
The target profit/fee has decreased by
The target profitfee has decreased by

This includes a decrease in target cost of $\{$, consisting of a 4 decrease in cost and a . ecrease in facilities capital cost of money, and a decrease in target fee of which is marget cost less facilities capital cost of money.

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, eutitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:
Target Cost
Target Fee


## Incentive Arrangement: Maximum Fee: <br> Minimum Fee:



## (Share Ratio: Government/Contractor)

Undernum: the amount by which the total allowable cost is less than the target cost until maximum fee is attained.

Overrun: for the amount by which the total allowable cost exceeds the target cost until minimum the total allowable cost is less than the target cost or decreased blents for every dollar that the total allowable cost exceeds the target cost. In no event shall the fee be greater than ercent or less that percent of the target cost. fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:
(e) Fee Payable.
(1) The fee payable under this contract shall be the target fee increased by ents for every dollar that B-18. TARGET COST. TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE,
AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

## SUBCLIN 0017AA - (Two SDD JLENS Systems)

a. Target cost:
b. Target fee:
c. Minimum incentive fee:
d. Maximum incentive fee:
e. Total target cost and target fee:


## 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 8,573.00$ from $\$ 1,463,984,091.81$ to $\$ 1,463,992,664.81$.

SUBCLIN 0017AA:

MD: 2102040 5L 5L68 P172419E555L 255Y 4M0J732000 S01021 4M0J732000/04MJLE/4M5 was increased by $\$ 8,573.00$ from $\$ 0.00$ to $\$ 8,573.00$

The contract ACRN MD has been added.


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding

THIS
MODIFICATION
CUMULATIVE TOTAL*


## 002002

* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)


## 4. SECTION H - SPECLAL CONTRACT REQUIREMENTS is changed as follows:

## Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CL.IN 0017. SYSTEM

DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs a. and b., are revised as follows:
a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of $51,575,874,550$ includes a target cost of (which includes $S$ of cost and racilities capital cost of money) and a target incentive fee of which is? farget cost less facilities capital cost of money.
b. Cost Incentive.

| (1) The target fee payable under SubCLIN 0017AA is | he target cost less facilities capital cost of money | (b)(b) |
| :---: | :---: | :---: |
| 1 amount equal to |  | (b)(c) |
| (2) The maximum fee payable under SubCLIN O017AA money $\qquad$ amount equal to $\qquad$ | the target cost less facilities capital cost of | $\begin{aligned} & (b)(4) \\ & (b)(4) \end{aligned}$ |
| (3) The minimum fee payable under SubCLIN 0017AA $\qquad$ an amount equal to $\square$ | the target cost less facilities capital cost of money | $\text { (b) } \times 4$ |

(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio on . onernmentrer for actual costs less than the target cost, and a ratio d Overnment / ntractor for actual costs greater than the target cost range applied according to Paragraph H-19(c)(1).
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.
(1) A maximum "flat zone" will be established at the target cost value of
conduct of milestones below. The "flat zone" over which the contractor will earm target fee is for eligible costs fre conduct of milestomes below. The "flat zone" over which the contractor will earn target fee is for eligible costs from - 10 \$ $\$$ once the program milestones set forth below are conducted.
(a
Functionar Review NLT 2nd Quarter, Fiscal Year 2007 . (It is hereby ackeow the conduct of the SDD System
Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of that
Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the
conclusion of the contract. Reference letter, dated 5 March 2007 from
(b) W of the maximum benefit of the "Ilat zone", earned by the conduct of SDD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the govermoent that Raytheon completed the requirement for this flat zone and eamed the "Flat Zone" schedule incentive on, Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, from
(2) An additional performance incentive fee pool of $\quad$ (maximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:
(a)
(maximum) earned based on successful conduct of technical performance defined by SCR-I.
(b) (maximum) earned based on successful conduct of technical performance defined by SCR-2.
(c)
(maximum) earned based on successful conduct of technical performance defined by SCR-3.
(d) naximum) earned based on successful conduct of technical performance defined by LUT.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section $J$ attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is earned.
(3) For Earned Value and cost reporting purposes, the target cost value of will be used.

## d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.
5. The following is an update to Modification P00217 showing a summary of funding by ACRN through Modification P00218:

| ACRN | FUNDING |  |
| :--- | ---: | ---: |
| AA |  |  |
| AA |  | $440,100.00$ |
| AB |  | $2,298,235.00$ |
| AC |  | $17,832,987.00$ |
| AD |  | 0.00 |
| AE |  | $\mathbf{7 , 5 0 0 , 0 0 0 . 0 0}$ |
| AF |  | $3,300,000.00$ |
| AG |  | $17,192,400.00$ |
| AH |  | $700,000.00$ |
| AJ |  | $200,000.00$ |
| AK |  | $85,000.00$ |
| AL |  | $45,000.00$ |
| AM |  | $17,045,000.00$ |
| AN |  | $5,800.00$ |

## 002004

| AP | 20,779,000.00 |
| :---: | :---: |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |
| KW | 20,000.00 |
| KX | 60,000.00 |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |

## 002005

| LG | $\mathbf{6 2 , 0 0 0 . 0 0}$ |
| :--- | ---: |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 262,714,555.00$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |

6. The following is an update to Modification P00217 showing a summary of funding by CLIN by ACRN through Modification P00218:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
| CLIN 0003 | AF | 3,300,000.00 |  |
| CLIN 0003 | AG | 17,192,400.00 |  |
| CLIN 0003 | AH | 700,000.00 |  |
| CLIN 0003 | AM | 17,045,000.00 |  |
| CLIN 0003 | AN | 5,800.00 |  |
| CLIN 0003 | AP | 20,779,000.00 |  |
| CLIN 0003 | AS | 0.00 |  |
| CLIN 0003 | AT | 6,984,678.52 | . |
| CLIN 0003 | AW | 100,000.00 |  |
| CLIN 0003 | AY | 550,000.00 |  |
|  |  |  | 94,288,100.52 |

## 002006

| CLIN 0005 | BA | $24,527,878.00$ |
| :--- | ---: | ---: |
| CLIN 0005 | BB | $146,000.00$ |
| CLIN 0005 | BC | $72,000.00$ |
| CLIN 0005 | BD | $85,000.00$ |
| CLIN 0005 | BE | $100,000.00$ |
| CLIN 0005 | BF | $100,000.00$ |
| CLIN 0005 | BG | $1,975,321.00$ |
| CLIN 0005 | BH | $38,018,908.00$ |
| CLIN 0005 | BL | 0.00 |
| CLIN 0005 | BZ | 0.00 |

## CLIN 0007AA BP

$10,199,288.50$

$$
65,025,107.00
$$

| CLIN 0009AA | AQ | $\mathbf{4 5 , 1 0 6 . 0 0}$ |
| :--- | :--- | ---: |
| CLIN 0009AA | AV | 0.00 |
| CLIN 0009AA | BK | $256,545.00$ |
| CLIN 0009AA | BM | $125,000.00$ |
| CLIN 0009AA | BN | $21,315.00$ |

200,000.00
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00 9,000.00

$$
10,199,288.50
$$

$\qquad$

CLIN 0009AB AJ AK CLIN 0009AB AL CLIN 0009AB AQ AR BK CLIN 0009AB BN CLIN 0009AB BU CLIN 0009AB BV

## CLIN 0013

CLIN 0013
CLIN 0013
AU
AX
AY
CLIN 0013
$A Z$
CLIN 0013
BJ

| CLIN 0017 | BW | 0.00 |
| :--- | :--- | ---: |
| CLIN 0017 | KM | 0.00 |
|  |  |  |
|  |  |  |
| CLIN 0017AA | BY | $3,880,000.00$ |
| CLIN 0017AA | BX | $1,146,000.00$ |
| CLIN 0017AA | BW | $84,896,852.00$ |

7,970,000.00
3,396,000.00
0.00
$19,412,000.00$ 7,898,834.79 38,676,834.79
$869,034,00$

| $869,034,00$ |
| ---: |

38,676,834.7.
0.00
0.00 $\qquad$


## 002008

| CLIN 0020AA | KN | 0.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021 AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |


| CLIN 0028 | LM | $329,972.00$ |
| :--- | :--- | ---: |
| CLIN 0028 | MA | $2,982,442.00$ |
|  |  |  |

7. In consideration of the modification agreed to herein as complete equitable adjustment for the actual costs incurred, submitted via Raytheon letter JLENS-23414-10-095, in support of the preparation of a proposal in response to Modification P00199 prior to it being rescinded, the Contractor hereby releases the Government from any and all liability under this contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposal for adjustment.
(End of Summary of Changes)

| AMENDMENT/MODIFICATION NO. 3219 | $\begin{gathered} \text { 3. EFFBCTIVEDATB } \\ 05-\text { Oct-2010 } \end{gathered}$ | 4. REQUSITION/PURCHASE REQ.NO. |  | 5. PROIECT NO.(ffepplicable) |
| :---: | :---: | :---: | :---: | :---: |
|  | W9113M | 7. ADMINSIERED BY (Ifother then item6) <br> DCMA RAFTHEON <br> 50 APPLE HIL DRIVE <br> MßT2FR2 <br> TENKSEURY MA 01876 | CODE | S2205A |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., Streat, County, State and Zip Code) RAYTHEON COMPANY <br> 350 Lowell 8 T. <br> ANDOVER MA 0181D-9400 |  |  | 9.A. AMENDIENT OF SOLICITATION NO. |  |
|  |  |  | 9B. DATED (SEE ITEM 11) |  |
|  |  |  | 10A. MOD OF OONTRACT/ORDER NO. DASC60-98-C-0001 |  |
|  |  |  | 10B. DATED (SEE TTEM 13)30-Jan-1998 |  |
| 11. THIS ITEM ONLY APPLIES'TO AMENDMENTS OF SOLICIT ATIONS |  |  |  |  |
| The above numbered solicitation is amended as set forth in Item 14. The hour end date specified fer reccipt ofOfir |  |  | is extended, $\square$ is not extended. |  |

Offrmut acknowledge recsipt of this amendment prior to the hour and dete apecified in the solicitation or as amended by one of the following urethods:
(a) By completing Items 8 end 15, and retuming Copies of the ernendment; (b) By acknowledging recesipt ofthis emendment on each copy of the offrr subnitted or (c) By separmate letter or telegrem which indudes a refrence to the solicitation and ammandent numbers. FAILURB OF YOUR ACKNOWLEDGMENT TO BE RECBIVED AT THE PLACB DESIGNATBD FOR THE RECEIP T OF OFFERS PRIOR TO THE HOUR AND DATE SPBCIFIED MAY RESULTIN
REIBCTION OF YOUR OFFER Ifby virtuc ofthis emmendmant you desire to change an ofir already submitted, such change may be made by tolegrean or lettre, provided esch telogram or letter makes refrence to the solicitution and this emendment, and is received prior to the opening hour and date specified.
12. ACOOUNTING AND APPROPRIATION DATA (If required) See Schedule

## 13. THIS ITEM APPLIESONLY TO MODIFICATIONS OF OONTRACTSORDERS

IT MODIFIES THE OONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
A. THISCHANGE ORDER ISISSUED PURSUANT TO: (Specify authority) THE CHANGESSET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.


## SUMMARY OF CHANGES

## SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ \mathbf{2 3 , 0 0 0 , 0 0 0 . 0 0}$ from $\$ 1,423,388,769.02$ to $\$ 1,446,388,769.02$.

SUBCLIN 0017AA:
ME: 2112040 SL 5L68 P172419E555L 255Y 4M1J730000 S01021 was increased by \$23,000,000.00 from $\$ 0.00$ to $\$ 23,000,000.00$

The contract ACRN ME has been added.
(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1.SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 40,000,000.00$ from $\$ 1,486,992,664,81$ to $\$ 1,526,992,664.81$.

SUBCLIN 0017AA:
ME: 2112040 SL 5L68 P172419E555L 255Y 4M1J730000 S01021 was decreased by \$23,000,000.00 from $\$ 23,000,000,00$ to $\$ 0.00$

MF: 2112040 SL 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 63,000,000.00$ from $\$ 0.00$ to $\$ 63,000,000.00^{*}$

The contract ACRN MF has been added.
Target Cost, Target Fee, and Total for the above increase of \$ * is distributed as follows and includes an increase in target cost of $\$$ ( $\$$ facilities capital cost of money) and an increase in target incentive fee of which of target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | ---: |
| Target Fee |  |
| Total | $\$ 63,000,000^{*}$ |
|  |  |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Fuil Funding

*NOTE: This $\$ 63,000,000$ increase includes $\$ 23,000,000$ that was obligated in Modification P00219 but is moved via this modification from ACRN ME to ACRN MF in order to correct an error in the accounting classification. The increase in the total funded amount via Modification P00220 is $\$ 40,000$.
** These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)
2. The following is an update to Modification P00218 showing a summary of funding by ACRN through Modification P00220:

## ACRN FUNDING

| AA | 440,100.00 |
| :---: | :---: |
| AB | 2,298,235.00 |
| AC | 17,832,987.00 |
| AD | 0.00 |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK | 85,000.00 |
| AL | 45,000,00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000,00 |
| KN | 0.00 |

## 002015

| KQ | 92,811.00 |
| :---: | :---: |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |
| KW | 20,000.00 |
| KX | 60,000.00 |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |
| LG | 62,000.00 |
| LH | 400,000.00 |
| LJ | 7,476.00 |
| LK | \$281,575,897.00 |
| LL | \$173,798.00 |
| LM | \$1,410,376.00 |
| LN | \$630,061.00 |
| LP | \$83,200.00 |
| LQ | \$235,566.00 |
| LR | \$125,000,00 |
| LS | \$6,069,616.00 |
| LT | \$530,377.00 |
| LU | \$9,100,000.00 |
| LV | \$1,957,265.00 |
| LW | \$255,567.00 |
| LX | \$68,000.00 |
| LY | \$262,714,555.00 |
| LZ | \$1,751,384.00 |
| MA | \$2,982,442.00 |
| MB | \$375,000.00 |
| MC | \$2,283,481.00 |
| MD | \$8,573.00 |
| ME | \$0.00 |
| MF | \$63,000,000,00 |

3. The following is an update to Modification P00218 showing a summary of funding by CLIN by ACRN through Modification P00220:

| CLIN | ACRN | FUNDING AMT |  |
| :--- | :--- | ---: | :--- |
|  |  |  |  |
| CLIN 0001 TOTAL |  |  |  |
| CLIN 0001 | AA | $440,100.00$ |  |
|  | AD | 0.00 |  |
|  |  |  | $440,100.00$ |

## 002016

CLIN 0003

| AB | $2,298,235.00$ |
| :--- | ---: |
| AC | $17,832,987.00$ |
| AD | 0.00 |
| AE | $7,500,000.00$ |
| AF | $3,300,000.00$ |
| AG | $17,192,400.00$ |
| AH | $700,000.00$ |
| AM | $17,045,000.00$ |
| AN | $5,800.00$ |
| AP | $20,779,000.00$ |
| AS | 0.00 |
| AT | $6,984,678.52$ |
| AW | $100,000.00$ |
| AY | $550,000.00$ |

447,966.00

24,527,878.00
$146,000.00$
72,000.00
85,000.00
$100,000.00$
$100,000.00$
1,975,321.00
38,018,908.00
0.00
0.00

10,199,288.50

45,106.00
0.00

256,545.00
125,000.00
21,315.00
$\begin{array}{r}94,288,100.52 \\ \hline\end{array}$
$-65,025,107,00$

CLIN 0007AA BP

CLIN 0009AA
AQ CLIN 0009AA

BK CLIN 0009AA

BM CLIN 0009AA

BN

| CLIN 0009AB | AJ | $200,000.00$ |
| :--- | :--- | ---: |
| CLIN 0009AB | AK | $85,000.00$ |
| CLIN 0009AB | AL | $45,000.00$ |
| CLIN 0009AB | AQ | $59,894.00$ |
| CLIN 0009AB | AR | $35,000.00$ |
| CLIN 0009AB | BK | $3,455.00$ |
| CLIN 0009AB | BN | $81,685.00$ |
| CLIN 0009AB | BU | $350,000.00$ |


| CLIN 0009AB | BV | 9,000.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 869,034.00 |
| CLIN 0013 | AU | 7,970,000.00 |  |
| CLIN 0013 | AX | 3,396,000.00 |  |
| CLIN 0013 | AY | 0.00 |  |
| CLIN 0013 | AZ | 19,412,000.00 |  |
| CLIN 0013 | BJ | 7,898,834.79 |  |
|  |  |  | 38,676,834.79 |
| CLIN 0017 | BW | 0.00 |  |
| CLIN 0017 | KM | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AA | BY | 3,880,000.00 |  |
| CLIN 0017AA | BX | 1,146,000.00 |  |
| CLIN 0017AA | BW | 84,896,852.00 |  |
| CLIN 0017AA | BZ | 0.00 |  |
| CLIN 0017AA | KM | 192,793,000.00 |  |
| CLIN 0017AA | KN | 0.00 |  |
| CLIN 0017AA | KQ | 66,151.00 |  |
| CLIN 0017AA | KS | 0.00 |  |
| CLIN 0017AA | KT | 386,204,200.00 |  |
| CLIN 0017AA | KU | 2,203,183.00 |  |
| CLIN 0017AA | KY | 0.00 |  |
| CLIN 0017AA | LC | 200,000.00 |  |
| CLIN 0017AA | LD | 7,943,648.00 |  |
| CLIN 0017AA | LE | 0.00 |  |
| CLIN 0017AA | LH | 400,000.00 |  |
| CLIN 0017AA | LJ | 7,476.00 |  |
| CLIN 0017AA | LK | 281,575,897,00 |  |
| CLIN 0017AA | LQ | 235,566.00 |  |
| CLIN 0017AA | LS | 6,069,616.00 |  |
| CLIN 0017AA | LT | 530,377.00 |  |
| CLIN 0017AA | LU | \$9,100,000.00 |  |
| CLIN 0017AA | LV | \$1,957,265.00 |  |
| CLIN 0017AA | LW | \$255,567.00 |  |
| CLIN 0017AA | LX | \$68,000.00 |  |
| CLIN 0017AA | LY | \$262,714,555.00 |  |
| CLIN 0017AA | MB | \$375,000.00 |  |
| CLIN 0017AA | MC | \$2,283,481.00 |  |
| CLIN 0017AA | MD | \$8,573.00 |  |
| CLIN 0017AA | ME | \$0.00 |  |
| CLIN 0017AA | MF | \$63,000,000.00 |  |
|  |  |  | 307,914,407.00 |

## 002018



## 002019

| CLIN 0024 | LA | 13,508.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000,00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | $L Z$ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
|  |  |  | 3,312,414.00 |

(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

1.SECTION B - SUPPLIES OR SERVICES AND PRICES

SUBCLIN 002803 is added as follows:

| ITEM NO | SUPPLIES/SERVICES | QUANTITY UNIT | UNIT PRICE |  |
| :--- | :--- | :--- | :--- | :--- |
| 002803 |  |  |  |  |
|  | Funding for CLIN 0028 |  |  |  |

TARGET COST
TARGET FEE
TOTAL TGT COST + FEE
$\$ 6,262,095.00$

ACRN MG $\$ 6,262,095.00$
CIN: 000000000000000000000000000000

## 2. SECTION G-CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 6,262,095.00$ from $\$ 1,526,992,664.81$ to $\$ 1,533,254,759.81$.

SUBCLIN 002803:
Funding on SUBCLIN 002803 is initiated as follows:
ACRN: MG
CIN: 000000000000000000000000000000
Acctng Data: 2112040 5L 5L68 P172419E555L 255Y 4M1J730200 S01021 4M1J730200/14MJLE/4M5
Increase: $\$ 6,262,095.00$
Total: \$6,262,095.00
Target Cost, Target Fee, and Total for the above increase of $\$ 6,262,095$ is distributed as follows and includes a

$$
002022
$$



CLIN 0028 :
PRIOR MODIFICATION TOTAL

THIS

CUMULATIVE

Amount Required for Full Funding, Including
(1) Fee:

Amount Allotted Under the LOF Clause for
(2) Payment of Costs:

Amount Separately Obligated for Payment of
(3) Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding

\$ 3,312,414
\$6,262,095
\$ 9,574,509
$\mathbf{\$ 1 4 , 1 2 6 , 5 9 4}$
$(\$ 6,262,095)$
\$7,864,499
$\mathbf{\$ 1 7 , 4 3 9 , 0 0 8}$
\$
0
$\mathbf{\$ 1 7 , 4 3 9 , 0 0 8}$

The note on page 2 of Modification P00220 is corrected as follows (changes are shown in bold):
*NOTE: This $\$ 63,000,000$ increase includes $\$ 23,000,000$ that was obligated in Modification P00219 but is moved via this modification from ACRN ME to ACRN MF in order to correct an error in the accounting classification. The increase in the total funded amount via Modification P00220 is $\mathbf{\$ 4 0 , 0 0 0 , 0 0 0}$.
3. The following is an update to Modification P00220 showing a summary of funding by ACRN through Modification P00221:

ACRN FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |
| AD | 0.00 |
| AE | $7,500,000.00$ |
| AF | $3,300,000.00$ |
| AG | $17,192,400.00$ |
| AH | $700,000.00$ |
| AJ | $200,000.00$ |
| AK | $85,000.00$ |
| AL | $45,000.00$ |
| AM | $17,045,000.00$ |
| AN | $5,800.00$ |
| AP | $20,779,000.00$ |


| AQ | $105,000.00$ |
| :--- | ---: |
| AR | $35,000.00$ |
| AS | 0.00 |
| AT | $6,984,678.52$ |
| AU | $7,970,000.00$ |
| AV | 0.00 |
| AW | $100,000.00$ |
| AX | $3,396,000.00$ |
| AY | $550,000.00$ |
| AZ | $19,412,000.00$ |
| BA | $24,527,878.00$ |
| BB | $146,000.00$ |
| BC | $72,000.00$ |
| BD | $85,000.00$ |
| BE | $100,000.00$ |
| BF | $100,000.00$ |
| BG | $1,975,321.00$ |
| BH | $38,018,908.00$ |
| BJ | $7,898,834.79$ |
| BK | $260,000.00$ |
| BL | 0.00 |
| BM | $125,000.00$ |
| BN | $103,000.00$ |
| BP | $10,199,288.50$ |
| BU | $350,000.00$ |
| BV | $9,000.00$ |
| BW | $84,896,852.00$ |
| BX | $1,146,000.00$ |
| BY | $3,880,000.00$ |
| BZ | $190,000.00$ |
| KL | $118,250.00$ |
| KM | $192,793,000.00$ |
| KN | 0.00 |
| KQ | $92,811.00$ |
| KR | 0.00 |
| KS | 0.00 |
| KT | $62,000.00$ |
| KU | $2,203,183.00$ |
| KV | $65,000.00$ |
| KW | $20,000.00$ |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $1,943,648.00$ |
| LE | $10,000.00$ |
| LF | LG |


| LH | $400,000.00$ |
| :--- | ---: |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 262,714,555.00$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 0.00$ |
| MF | $\$ 63,000,000.00$ |
| MG | $\$ 6,262,095.00$ |

4. The following is an update to Modification P00220 showing a summary of funding by CLIN by ACRN through Modification P00221:

| CLIN | ACRN | FUNDING AMT |  |
| :--- | :--- | ---: | :--- |
| CLIN TOTAL |  |  |  |
| CLIN 0001 |  |  |  |
| CLIN 0001 | AA | $440,100.00$ |  |
|  | AD | 0.00 |  |
|  |  |  |  |
|  |  | $2,298,235.00$ |  |
| CLIN 0003 | AB | $17,832,987.00$ |  |
| CLIN 0003 | AC | 0.00 |  |
| CLIN 0003 | AD | $7,500,000.00$ |  |
| CLIN 0003 | AE | $3,300,000.00$ |  |
| CLIN 0003 | AF | $17,192,400.00$ |  |
| CLIN 0003 | AG | $700,000.00$ |  |
| CLIN 0003 | AH | $17,045,000.00$ |  |
| CLIN 0003 | AM | $5,800.00$ |  |
| CLIN 0003 | AN | $20,779,000.00$ |  |
| CLIN 0003 | AP | 0.00 |  |
| CLIN 0003 | AS | $6,984,678.52$ |  |
| CLIN 0003 | AT | $100,000.00$ |  |
| CLIN 0003 | AW | $550,000.00$ |  |

## 002025

|  |  |  | 94,288,100.52 |
| :---: | :---: | :---: | :---: |
| CLIN 0005 | BA | 24,527,878.00 |  |
| CLIN 0005 | BB | 146,000.00 |  |
| CLIN 0005 | BC | 72,000.00 |  |
| CLIN 0005 | BD | 85,000.00 |  |
| CLIN 0005 | BE | 100,000.00 |  |
| CLIN 0005 | BF | 100,000.00 |  |
| CLIN 0005 | BG | 1,975,321.00 |  |
| CLIN 0005 | BH | 38,018,908.00 |  |
| CLIN 0005 | BL | 0.00 |  |
| CLIN 0005 | BZ | 0.00 |  |
|  |  |  | 65,025,107.00 |
| CLIN 0007AA | BP | 10,199,288.50 |  |
|  |  |  | 10,199,288.50 |
| CLIN 0009AA | AQ | 45,106.00 |  |
| CLIN 0009AA | AV | 0.00 |  |
| CLIN 0009AA | BK | 256,545.00 |  |
| CLIN 0009AA | BM | 125,000.00 |  |
| CLIN 0009AA | BN | 21,315.00 |  |
|  |  |  | 447,966.00 |
| CLIN 0009AB | AJ | 200,000.00 |  |
| CLIN 0009AB | AK | 85,000.00 |  |
| CLIN 0009AB | AL | 45,000.00 |  |
| CLIN 0009AB | AQ | 59,894.00 |  |
| CLIN 0009AB | AR | 35,000.00 |  |
| CLIN 0009AB | BK | 3,455.00 |  |
| CLIN 0009AB | BN | 81,685.00 |  |
| CLIN 0009AB | BU | 350,000.00 |  |
| CLIN 0009AB | BV | 9,000.00 |  |
|  |  |  | 869,034.00 |
| CLIN 0013 | AU | 7,970,000.00 |  |
| CLIN 0013 | AX | 3,396,000.00 |  |
| CLIN 0013 | AY | 0.00 |  |
| CLIN 0013 | AZ | 19,412,000.00 |  |
| CLIN 0013 | BJ | 7,898,834.79 |  |
|  |  |  | 38,676,834.79 |
| CLIN 0017 | BW | 0.00 |  |
| CLIN 0017 | KM | 0.00 |  |
|  |  |  | 0.00 |

## 002026



|  |  |  | 173,798.00 |
| :---: | :---: | :---: | :---: |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
|  |  | $2028$ |  |


| CLIN 0026 | LN | 630,061.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1.SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 8,000,000.00$ from $\$ 1,533,254,759.81$ to $\$ 1,541,254,759.81$.

SUBCLIN 0017AA:

MF: 2112040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 8,000,000.00$ from $\$ 63,000,000.00$ to $\$ 71,000,000.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 8,000,000$ is distributed as follows and includes an increase in target cost of $\quad 9$ of cost and facilities capital cost of money) and an increase in target incentive fee of hich $\square$ of target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | :--- |
| Target Fee |  |
| Total | $\$ 8,000,000$ |
|  |  |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph $c$., is revised to read as follows:

SUBCLIN 0017AA :


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00221 showing a summary of funding by ACRN through Modification P00222:

ACRN FUNDING

AA
440,100.00
AB
2,298,235.00

| AC | 17,832,987.00 |
| :---: | :---: |
| AD | 0.00 |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK | 85,000.00 |
| AL | 45,000.00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |

## 002032

| KV | $65,000.00$ |
| :--- | ---: |
| KW | $20,000.00$ |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 262,714,555.00$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 9.00$ |
| MF | $\$ 7,000,000.00$ |
| MG | $\$ 6,262,095.00$ |
|  |  |

3. The following is an update to Modification P00221 showing a summary of funding by CLIN by ACRN through Modification P00222:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
|  |  | $0020$ |  |


| CLIN 0003 | AF |
| :--- | :--- |
| CLIN 0003 | AG |
| CLIN 0003 | AH |
| CLIN 0003 | AM |
| CLIN 0003 | AN |
| CLIN 0003 | AP |
| CLIN 0003 | AS |
| CLIN 0003 | AT |
| CLIN 0003 | AW |
| CLIN 0003 | AY |

## CLIN 0005

CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005 CLIN 0005 CLIN 0005 CLIN 0005 CLIN 0005

CLIN 0007AA BP
BA
BB
BC
BD
BE
BF
BG
BH
BL
BZ


CLIN 0009AA
CLIN 0009AA
AQ

CLIN 0009AA
CLIN 0009AA
CLIN 0009AA
AV
BK
BM
BN

CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB

CLIN 0013
AU
CLIN 0013

AJ
AK
AL
AQ
AR
BK
BN
BU
BV
$3,300,000.00$
$17,192,400.00$
$700,000.00$
$17,045,000.00$
$5,800.00$
$20,779,000.00$
0.00
$6,984,678.52$
$100,000.00$
$550,000.00$
$94,288,100.52$

24,527,878.00
$146,000.00$
72,000.00
85,000.00
100,000.00
$100,000.00$
1,975,321.00
38,018,908.00 0.00 0.00

$$
65,025,107.00
$$

$10,199,288.50$
$10,199,288.50$

45,106.00
0.00

256,545.00
125,000.00
21,315.00
447,966.00

200,000.00
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00
9,000.00 $\qquad$

7,970,000.00
3,396,000.00


## 002035

| CLIN 0017AC | $B Z$ | 190,000.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021 AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
|  |  | $2036$ |  |


| CLIN 0024 | LP | $83,200.00$ |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)

| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT |  |  |  | 1. CONTRACTID CODE V | PAGE OF PAGES <br> 1 11 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 2. AMENDMENT/MODIFICATION NO. P00223 | 3. EFFECTIVE DATS 18-Nov-2010 | 4. REQUISITION/PURCHASE REQ.NO. |  | 5. PROJECT NO.(Ifapplicible) |  |  |
| 6. LSSUED BY USASMDCJARSTRAT SMDC-RDC POROX 150 HUNTSVALEAL 38907 -380 | W9113M | 7.ADMINISTERED BY (Ifotherthan item6) DCMARAYTHEON SOAPPLEHILL ORNE MS TRFR2 tewnseuayma 01876 |  | CODE |  |  |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., Sreet, Counly, Sate and Zip Code) FAYTHEON COMPANY 3 solowell st. <br> ANDOVER MAOTEIO 400 |  |  |  | A. AMENDMENT OF SOLICITATION NO. |  |  |
|  |  |  |  | B. DATED (SEE ITEM II) |  |  |
|  |  |  |  | 10A.MOD. OF CONTRACT/ORDER NO. BASG60-98-C-0001 |  |  |
|  |  |  |  |  |  | $\begin{array}{\|l\|l} \hline \text { 10B. DATED (SEE ITEM 13) } \\ \times & \text { 30-Jan-1998 } \end{array}$ |
| 11. THISITEM ONLY APPLIESTO AMENDMENTS OP SOLICITATIONS |  |  |  |  |  |  |
| The ahove numberex solicitition is amended os set forth in liem 14. The hour and doxe speciled for recelpt of0fer $\square$ is axtended. $\square$ is not excended. Ofer must acknowledge recelpt of his amendreeat prior to the hour and dace speclied in the solicitation or as areaded by one ofthe flliowing methods: (a) By compleiling levers 8 and 15 , and retuming $\qquad$ copies ofthe amendmant; (b) By act nowledging receipt ofthis amendment on eech copy ofthe offer subaitted; or (c) By separme letter or relegram which inciudes a meterence to the solicitation and mrendmen numbers. FAILURE OF YOUR ACKNOWLEDCMENTTO BE RECEIVED ATTHE PLACE DESIGNATED FOR THE RECEIPTOF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULTIN REJECTION OF YOUR OFFER. Ifby vintue ofthis anencment you desife to change an ofer ofready subnitted, such change nay be rade by telegramor letier. provided each rel egromor lecter makes refarcace to the solicitation and ibls ammanman, mod is roceived prior to the opening hour nod dave specilled. |  |  |  |  |  |  |
| 12. ACCOUNTING AND APPROPRIATION DATA (If required) See Schedule |  |  |  |  |  |  |
| 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTSORDERS. IT MODIFES THE CONTRACT/ORDER NO. AS DESCRUBED IN ITEM 14. |  |  |  |  |  |  |
| A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. |  |  |  |  |  |  |
| B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODHFIED TO REFLECT THE ADMINISTRATIVE CHANCES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). |  |  |  |  |  |  |
| $\begin{aligned} & \text { C THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORIT Y OF: } \\ & \text { FAR } 52.232-22, \text { "Linkation of Funds" and Mutual Agreemnant } \\ & \hline \end{aligned}$ |  |  |  |  |  |  |
| D. OTHER (Specify type of modification and authority) |  |  |  |  |  |  |
| E. IMPORTANT: Contractor $\square$ is not, $\bar{X}$, is required to sign this document and return $\quad 1$ copies to the issuing office. |  |  |  |  |  |  |
| 14. DESCRIPTION OF AMENDMENTMODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) <br> Modificalion Control Number: <br> To increase and fund SubCLN 0017 nrint the amount of $\$ 213,390$ as settlement of the equitable adjusitment proposal submitted by the cortractor in response to the government tectinical directive (TD), dated 12 Nay 2010. A subsequent lechnical direcllve, dated 2 Sentamber 2010 _sicersedias the 12 May 2010 TD and shoutd be ullized to determine the required PF backup capabilities for the. cormponents FTS frequency and tones configuration for <br> the changes outhed in the 21 Seplenber 2010 TD have ne cost Impact on the proposal subritted by the contractor. Additional incremental funding in the amount of $\$ 9,000,000$, unrelated to the settlement of this equitable adjustment, is also provided vala thls modification. |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  | STANDARD FORM 30 (Rev, 10-83) <br> Prescribed by GSA <br> FAR (48 CFR) 53.243 |  |  |

## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1.SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by $\$ 213,390.00$ from $\$ 1,813, \$ 62,997.00$ to \$1,813,876,387.00.

836
2. SECTION B - SUPPLIES OR SERVICES AND PRICES

SUBCLIN 0017AA
The target cost has increased by 0 (b)(4)
The target profitfee has increased ble from $\$$
The total cost of this line item has increased by $\$ 213,390.00$ from $\$ 1,575,874,550.00$ to $\$ 1,576,087,940.00$.

This includes an increase in target cost o nsisting of a rase in facilities capital cost of money, and an increase in target fee of $\square$ hich target cost less facilities capital cost of money.

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

(Share Ratio: Government/Contractor)
Underrun: the amount by which the total allowable cost is less than the target cost until maximum fee is attained.

Overrun the amount by which the total allowable cost exceeds the target cost until minimum fee is attained.

FAR 52.216-10, NNCENTIVE, paragraph (e)(1), is stated as follows:
(e) Fee Payable.
(1) The fee payable under this contract shall be the target fee increased $h$ ts for every dollar that the total allowable cost is less than the target cost or decreased $b$, wothts for every dollar that the total allowable cost exceeds the target cost. In no event shall the fee be greater tha rent or less the rent of the target cost.

## B-18. TARGET COST, TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA - (Two SDD JLENS Systems)
a. Target cost:
b. Target fee:
c. Minimum incentive fee:
d. Maximum incentive fee:

e. Total target cost and target fee:
\$1,576,087,940

## 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 9,213,390.00$ from $\$ 1,541,254,759.81$ to $\$ 1,550,468,149.81$.

## SUBCLIN 0017AA:

MF: 2112040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 9,000,000.00$ from $\$ 71,000,000.00$ to $\$ 80,000,000.00$

Target Cost, Target Fee, and Total for the above increase o in distributed as follows and includes an increase in target cost of $\quad 59$ cost and facilities capital cost of money) and an increase in target incentive fee of $\longrightarrow$ which i target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | :--- |
| Target Fee |  |
| Total | $\$ 9,000,000$ |
|  |  |

MM: 2112040 5L 5L68 P172419E555L 255Y 4M1J731000 S01021 4M1J731000/14MJLE/4M5 was increased by $\$ 213,390.00$ from $\$ 0.00$ to $\$ 213,390.00$

The contract ACRN MH has been added.


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c ., is revised to read as follows:
SUBCLIN 0017AA :
THIS
MODIFICATION
PRIOR

## CUMULATIVE <br> TOTAL*

(1) Amount Required for Full Funding,

Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)


## 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is changed as follows:

Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN OO17. SYSTEM
DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs a and b., are revised as follows:
a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of $\$ 1,576,087,940$ includes a target cost $\quad$, hich includes $\$ \longrightarrow$ and acilities capital cost of money) and a target incentive fee of hich i_ target cost less tacilities capital cost of money.
b. Cost Incentive.

(5) Nothing stated in this clause shall take precedence over the clause 52.216-10-Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.

(b)
) $\longrightarrow$ of the maximum benefit of the "flat zone", earmed by the conduct of SDD Orbit Critical
Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and eamed the "Flat Zone" schedule incentive of $\$$ Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, from
(2) An additional performance incentive fee pool of
(maximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:
(a) Imaximum) earned based on successful conduct of technical performance defined by SCR-1.
(b)

(c) $\square$ laximum) earned based on successful conduct of technical performance defined by SCR-3.
(d) haximum) earned based on successful conduct of technical performance defined by LUT.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section J attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is earned.
(3) For Earned Value and cost reporting purposes, the target cost value of $\$ 1,446,946,473$ will be used.
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.
5. The following is an update to Modification P00222 showing a summary of funding by ACRN through Modification P00223:

## ACRN FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |
| AD | 0.00 |
| AE | $7,500,000.00$ |
| AF | $3,300,000.00$ |
| AG | $17,192,400.00$ |

## 002042

| AH |  | 700,000.00 |
| :---: | :---: | :---: |
| AJ | $\xi$ | 200,000.00 |
| AK |  | 85,000.00 |
| AL |  | 45,000.00 |
| AM |  | 17,045,000.00 |
| AN |  | 5,800.00 |
| AP |  | 20,779,000.00 |
| AQ |  | 105,000.00 |
| AR |  | 35,000.00 |
| AS |  | 0.00 |
| AT |  | 6,984,678.52 |
| AU |  | 7,970,000.00 |
| AV |  | 0.00 |
| AW |  | 100,000.00 |
| AX |  | 3,396,000.00 |
| AY |  | 550,000.00 |
| AZ |  | 19,412,000.00 |
| BA |  | 24,527,878.00 |
| BB |  | 146,000.00 |
| BC |  | 72,000.00 |
| BD |  | 85,000.00 |
| BE |  | 100,000.00 |
| BF |  | 100,000.00 |
| BG |  | 1,975,321.00 |
| BH |  | 38,018,908.00 |
| BJ |  | 7,898,834.79 |
| BK |  | 260,000.00 |
| BL |  | 0.00 |
| BM |  | 125,000.00 |
| BN |  | 103,000.00 |
| BP |  | 10,199,288.50 |
| BU |  | 350,000.00 |
| BV |  | 9,000.00 |
| BW |  | 84,896,852.00 |
| BX |  | 1,146,000.00 |
| BY |  | 3,880,000.00 |
| BZ |  | 190,000.00 |
| KL |  | 118,250.00 |
| KM |  | 192,793,000.00 |
| KN |  | 0.00 |
| KQ |  | 92,811.00 |
| KR |  | 0.00 |
| KS |  | 0.00 |
| KT |  | 386,377,998.00 |
| KU |  | 2,203,183.00 |
| KV |  | 65,000.00 |
| KW |  | 20,000.00 |
| KX |  | 60,000.00 |
| KY |  | 25,000.00 |
| KZ |  | 25,000.00 |

## 002043

| LA | $13,508.00$ |
| :--- | ---: |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 9,100,000.00$ |
| LU | $\$ 1,957,265.00$ |
| LV | $\$ 255,567.00$ |
| LW | $\$ 68,000.00$ |
| LX | $\$ 262,714,555.00$ |
| LY | $\$ 1,751,384.00$ |
| LZ | $\$ 2,982,442.00$ |
| MA | $\$ 375,000.00$ |
| MB | $\$ 2,283,481.00$ |
| MC | $\$ 8,573.00$ |
| MD | $\$ 80,000,000.00$ |
| ME | $\$ 6,262,095.00$ |
| MF | $\$ 213,390.00$ |
| MG |  |
| MH |  |

6. The following is an update to Modification P00222 showing a summary of funding by CLIN by ACRN through Modification P00223:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
| CLIN 0003 | AF | 3,300,000.00 |  |
| CLIN 0003 | AG | 17,192,400.00 |  |
| CLIN 0003 | AH | 700,000.00 |  |
| CLIN 0003 | AM | 17,045,000.00 |  |
|  |  | 0204 |  |


| CLIN 0003 | AN | $5,800.00$ |
| :--- | :--- | ---: |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |
| CLIN 0003 | AW | $100,000.00$ |
| CLIN 0003 | AY | $550,000.00$ |

$24,527,878.00$
$146,000.00$
$72,000.00$
$85,000.00$
$100,000.00$
$100,000.00$
$1,975,321.00$
$38,018,908.00$
0.00
0.00
$94,288,100.52$

CLIN 0005
BA
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005

CLIN 0007AA
BP
$10,199,288.50$
10,199,288.50

| CLIN 0009AA | AQ | $45,106.00$ |
| :--- | :--- | ---: |
| CLIN 0009AA | AV | 0.00 |
| CLIN 0009AA | BK | $256,545.00$ |
| CLIN 0009AA | BM | $125,000.00$ |
| CLIN 0009AA | BN | $21,315.00$ |

$200,000.00$
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00 $9,000.00$

869,034.00

7,970,000.00
3,396,000.00
0.00

19,412,000.00
7,898,834.79


| $\begin{aligned} & \text { CLIN 0017AD } \\ & \text { CLIN 0017AD } \end{aligned}$ | $\begin{aligned} & \text { KN } \\ & \text { KS } \end{aligned}$ | 0.00 |  |
| :---: | :---: | :---: | :---: |
|  |  | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |

002047

| CLIN 0025 | LE | 1,173,850.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

7. In consideration of the modification agreed to herein as complete equitable adjustment for the Modifying Frequencies proposal submitted via Raytheon letter JLENS-23414-10124, dated 21 September 2010, the Contractor hereby releases the Government from any and all liability under this contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposal for adjustment.
(End of Summary of Changes)

| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT |  |  | 1. CONTRACTID CODE $V$ | page of pages |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 4MENDMENT/MODIFICATION NO. '224 | $\begin{gathered} \text { 3.EFFECTIVE DATE } \\ \text { 09-Dec-2010 } \end{gathered}$ | 4. REQUISITION/PURCHASE REQ. NO. | 5. PROJE | O.(Ifap |  |
|  | W9113M | 7. ADMINISTERED BY (Ifother than item6) DCMARAYTHEON 50 APPLE HIL DRNE MIS T2FR2 TEWKSEURY MA 01876 | CODE S2 |  |  |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip Code) RAYTHEON COMPANY 350 LOWEL ST. <br> ANDOVER MA 011010-4400 |  |  | 9A. AMENDMENT OF SOLICITATION NO. |  |  |
|  |  |  | 9B. DATED (SEE ITEM 11) |  |  |
|  |  |  | OA.MOD. OF CONTRACT/ORDER NO. DASG60-98-C-0001 |  |  |
|  |  |  | $\begin{aligned} & \text { 10B. DATED (SEE ITEM 13) } \\ & \text { 30-Jan-1998 } \\ & \hline \end{aligned}$ |  |  |
| 11. THS ITEM ONL Y APPLIES TO AMENDMENTS OF SOLICITATIONS |  |  |  |  |  |
| The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of ffer $\square$ is oxtended. $\square$ is not exten <br> Ofir must acknowledge recaipt ofthis ameadment prior to the hour and date specified in the solicitation or as amended by one ofthe following methods: <br> (a) By completing Items 8 and 15 , and retuming $\qquad$ copies ofthe amondrent; (b) By acknowledging receipt ofthis amendment on each copy of the offir submitted; or (c) By separate letter or telegram which includes a refirence to the solicitation and amendment numbers. FAIL URE OF YOUR ACKNOWLEDGMENTTO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPTOF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULTIN REJECTION OF YOUR OFFER. Ifby virtue ofthis amendment you desire to change an offer already submitted, auch change may be made by telegramor letter, provided oach telegramor letter makes reference to the solicitation and this amendment, and is received prior to the opecing hour and date specifed. |  |  |  |  |  |
| 12. ACCOUNTING AND APPROPRIATION DATA (If required)See Schedule |  |  |  |  |  |
| 13. THISITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACT SORDERS IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. |  |  |  |  |  |
| A. THIS CHANGF ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. |  |  |  |  |  |
| 13. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINSTRATIVE CHANGES (such as changes in payingoffice, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B). |  |  |  |  |  |
| C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORIT Y OF: |  |  |  |  |  |
| X D. OTHER (Specify type of modification and authority) UNLATERAL: FAR 52.232-22, "Limitation of Funds" |  |  |  |  |  |
| E. IMPORTANT: Contractor $x$ is not, | is required to sign this document and return copies to the issuing office. |  |  |  |  |
| 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) <br> - Modification Control Number: <br> To increase incremental funding for SubCLIN 0017 AA in the amount of $\$ 52,500,000$. |  |  |  |  |  |
| Except as provided herein, all terms and conditions ofthe document referenced in Item9A or 10A, as heretofore changed, remmins unchanged and in fill bree and effer. |  |  |  |  |  |
| 15A. NAME AND TITLE OF SIGNER (Type or print) |  |  |  |  |  |
| 15B. CONTRACTOR/OFFEROR (Signature of person authorized to sign) | 15C. DATE SIGNED | $\qquad$ |  | $\begin{aligned} & \text { 16C. DATE SIGNED }{ }^{y} \\ & 09-\text { Dec-2010 } \end{aligned}$ |  |
| EXCEPTIONTO $\operatorname{Fin}$ APPROVED BY OIRM $11-84$ | 30-105-04 <br> 002049 |  | STANDARD FORM 30 (Rev. 10-83)Prescribed by GSAFAR ( 48 CFR) 53.243 |  |  |

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1.SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 52,500,000.00$ from $\$ 1,550,468,149.81$ to $\$ 1,602,968,149.81$.

SUBCLIN 0017AA:

MF: 2112040 5L 5L68 Pl72419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 52,500,000.00$ from $\$ 80,000,000.00$ to $\$ 132,500,000.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 52,500,000$ is distributed as follows and includes an increase in target cost on cost and of facilities capital cost of money) and an increase in target incentive fee which is target cost less facilities capital cost of money.


Target Fee
Total


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


\$ 1,325,127,797
\$ 250,960,143

THIS
MODIFICATION

CUMULATIVE TOTAL* $\mathbf{\$ 1 , 5 7 6 , 0 8 7 , 9 4 0}$

* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00223 showing a summary of funding by ACRN through Modification P00224:

ACRN FUNDING
AA
440,100.00
AB
2,298,235.00
AC
17,832,987.00

| AD | 0.00 |
| :---: | :---: |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK' | 85,000.00 |
| AL | 45,000.00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |


| KW | $20,000.00$ |
| :--- | ---: |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 262,714,555.00$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 0.00$ |
| MF | $\$ 132,500,000.00$ |
| MG | $\$ 262,095.00$ |
| MH | $\$ 213,390.00$ |
|  |  |

3. The following is an update to Modification P00223 showing a summary of funding by CLIN by ACRN through Modification P00224:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
|  |  | $0020$ |  |


| CLIN 0003 | AF | $3,300,000.00$ |
| :--- | :--- | ---: |
| CLIN 0003 | AG | $17,192,400.00$ |
| CLIN 0003 | AH | $700,000.00$ |
| CLIN 0003 | AM | $17,045,000.00$ |
| CLIN 0003 | AN | $5,800.00$ |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |
| CLIN 0003 | AW | $100,000.00$ |
| CLIN 0003 | AY | $550,000.00$ |
|  |  |  |
|  |  | $24,527,878.00$ |
| CLIN 0005 | BA | $146,000.00$ |
| CLIN 0005 | BB | $72,000.00$ |
| CLIN 0005 | BC | $85,000.00$ |
| CLIN 0005 | BD | $100,000.00$ |
| CLIN 0005 | BE | $100,000.00$ |
| CLIN 0005 | BF | $1,975,321.00$ |
| CLIN 0005 | BG | $38,018,908.00$ |
| CLIN 0005 | BH | 0.00 |
| CLIN 0005 | BL | 0.00 |

$10,199,288.50$
CLIN 0007AA BP
-
$10,199,288.50$

45,106.00
0.00

256,545.00
125,000.00
21,315.00
447,966.00

| CLIN 0009AB | AJ | $200,000.00$ |
| :--- | :--- | ---: |
| CLIN 0009AB | AK | $85,000.00$ |
| CLIN 0009AB | AL | $45,000.00$ |
| CLIN 0009AB | AQ | $59,894.00$ |
| CLIN 0009AB | AR | $35,000.00$ |
| CLIN 0009AB | BK | $3,455.00$ |
| CLIN 0009AB | BN | $81,685.00$ |
| CLIN 0009AB | BU | $350,000.00$ |
| CLIN 0009AB | BV | $9,000.00$ |

7,970,000.00
CLIN 0013 AU
3,396,000.00


|  |  |  | 118,250.00 |
| :---: | :---: | :---: | :---: |
| CLIN 0017AC | BZ | 190,000.00 |  |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
|  |  | $2055$ |  |


| $\text { CLIN } 0024$ | KW | $20,000.00$ |  |
| :---: | :---: | :---: | :---: |
|  | LP | $83,200.00$ |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)


Except as provided herein, all terms and conditions of the document refrenced in Item9A or 10A, as heretofre changed, remains unchanged and in fill force and effer.


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 25,390,000.00$ from $\$ 1,602,968,149.81$ to $\$ 1,628,358,149.81$.

## SUBCLIN 0017AA:

LY: 2102040 5L 5L68 P172419E555L 255Y 4M0J730000 S01021 4M0J730000/04MJLE/4M5 was increased by $\$ 390,000.00$ from $\$ 262,714,555.00$ to $\$ 263,104,555.00$

MF: 2112040 5L 5L68 Pl72419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 25,000,000.00$ from $\$ 132,500,000.00$ to $\$ 157,500,000.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 25,390,000$ is distributed as follows and includes an increase in target cost of of cost and $\quad$ of facilities capital cost of money) and an increase in target incentive fee of of target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | ---: |
| Target Fee |  |
| Total | $\$ 25,390,000$ |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c ., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding

| PRIOR | THIS <br> MODIFICATION | $\begin{gathered} \text { CUMULATIVE } \\ \text { TOTAL* } \end{gathered}$ |
| :---: | :---: | :---: |
| \$1,576,087,940 | \$ 0 | \$ 1,576,087,940 |
| $\square$ b) (4) |  |  |
|  |  |  |
| \$ 1,377,627,797 | \$25,390,000 | \$ 1,403,017,797 |
| \$ 198,460,143 | (\$25,390,000) | \$ 173,070,143 |

* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00224 showing a summary of funding by ACRN through Modification P00225:

ACRN FUNDING

| AA | 440,100.00 |
| :---: | :---: |
| $A B$ | 2,298,235.00 |
| AC | 17,832,987.00 |
| AD | 0.00 |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK | 85,000.00 |
| AL | 45,000.00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |


| KT | $386,377,998.00$ |
| :--- | ---: |
| KU | $2,203,183.00$ |
| KV | $65,000.00$ |
| KW | $20,000.00$ |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 263,104,555.00$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 0.00$ |
| MF | $\$ 213,390.00$ |
| MG |  |
| MH | $\$ 262,095.00$ |
|  |  |
| M |  |

3. The following is an update to Modification P00224 showing a summary of funding by CLIN by ACRN through Modification P00225:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :--- | :--- | ---: | :--- |
| CLIN 0001 | AA | $440,100.00$ |  |
| CLIN 0001 | AD | 0.00 |  |
| CLIN 0003 | AB | $2,298,235.00$ |  |
|  |  | $0020,100.00$ |  |
|  |  | 000 |  |


| CLIN 0003 | AC | 17,832,987.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
| CLIN 0003 | AF | 3,300,000.00 |  |
| CLIN 0003 | AG | 17,192,400.00 |  |
| CLIN 0003 | AH | 700,000.00 |  |
| CLIN 0003 | AM | 17,045,000.00 |  |
| CLIN 0003 | AN | 5,800.00 |  |
| CLIN 0003 | AP | 20,779,000.00 |  |
| CLIN 0003 | AS | 0.00 |  |
| CLIN 0003 | AT | 6,984,678.52 |  |
| CLIN 0003 | AW | 100,000.00 |  |
| CLIN 0003 | AY | 550,000.00 |  |
|  |  |  | 94,288,100.52 |
| CLIN 0005 | BA | 24,527,878.00 |  |
| CLIN 0005 | BB | 146,000.00 |  |
| CLIN 0005 | BC | 72,000.00 |  |
| CLIN 0005 | BD | 85,000.00 |  |
| CLIN 0005 | BE | 100,000.00 |  |
| CLIN 0005 | BF | 100,000.00 |  |
| CLIN 0005 | BG | 1,975,321.00 |  |
| CLIN 0005 | BH | 38,018,908.00 |  |
| CLIN 0005 | BL | 0.00 |  |
| CLIN 0005 | BZ | 0.00 |  |
|  |  |  | 65,025,107.00 |
| CLIN 0007AA | BP | 10,199,288.50 |  |
|  |  |  | 10,199,288.50 |
| CLIN 0009AA | AQ | 45,106.00 |  |
| CLIN 0009AA | AV | 0.00 |  |
| CLIN 0009AA | BK | 256,545.00 |  |
| CLIN 0009AA | BM | 125,000.00 |  |
| CLIN 0009AA | BN | 21,315.00 |  |
|  |  |  | 447,966.00 |
| CLIN 0009AB | AJ | 200,000.00 |  |
| CLIN 0009AB | AK | 85,000.00 |  |
| CLIN 0009AB | AL | 45,000.00 |  |
| CLIN 0009AB | AQ | 59,894.00 |  |
| CLIN 0009AB | AR | 35,000.00 |  |
| CLIN 0009AB | BK | 3,455.00 |  |
| CLIN 0009AB | BN | 81,685.00 |  |
| CLIN 0009AB | BU | 350,000.00 |  |
| CLIN 0009AB | BV | 9,000.00 |  |
|  |  |  | 869,034.00 |


| CLIN 0013 | AU | 7,970,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0013 | AX | 3,396,000.00 |  |
| CLIN 0013 | AY | 0.00 |  |
| CLIN 0013 | AZ | 19,412,000.00 |  |
| CLIN 0013 | BJ | 7,898;834.79 |  |
|  |  |  | 38,676,834.79 |
| CLIN 0017 | BW | 0.00 |  |
| CLIN 0017 | KM | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AA | BY | 3,880,000.00 |  |
| CLIN 0017AA | BX | 1,146,000.00 |  |
| CLIN 0017AA | BW | 84,896,852.00 |  |
| CLIN 0017AA | BZ | 0.00 |  |
| CLIN 0017AA | KM | 192,793,000.00 |  |
| CLIN 0017AA | KN | 0.00 |  |
| CLIN 0017AA | KQ | 66,151.00 |  |
| CLIN 0017AA | KS | 0.00 |  |
| CLIN 0017AA | KT | 386,204,200.00 |  |
| CLIN 0017AA | KU | 2,203,183.00 |  |
| CLIN 0017AA | KY | 0.00 |  |
| CLIN 0017AA | LC | 200,000.00 |  |
| CLIN 0017AA | LD | 7,943,648.00 |  |
| CLIN 0017AA | LE | 0.00 |  |
| CLIN 0017AA | LH | 400,000.00 |  |
| CLIN 0017AA | LJ | 7,476.00 |  |
| CLIN 0017AA | LK | 281,575,897.00 |  |
| CLIN 0017AA | LQ | 235,566.00 |  |
| CLIN 0017AA | LS | 6,069,616.00 |  |
| CLIN 0017AA | LT | 530,377.00 |  |
| CLIN 0017AA | LU | \$9,100,000.00 |  |
| CLIN 0017AA | LV | \$1,957,265.00 |  |
| CLIN 0017AA | LW | \$255,567.00 |  |
| CLIN 0017AA | LX | \$68,000.00 |  |
| CLIN 0017AA | LY | \$263,104,555.00 |  |
| CLIN 0017AA | MB | \$375,000.00 |  |
| CLIN 0017AA | MC | \$2,283,481.00 |  |
| CLIN 0017AA | MD | \$8,573.00 |  |
| CLIN 0017AA | ME | \$0.00 |  |
| CLIN 0017AA | MF | \$157,500,000.00 |  |
| CLIN 0017AA | MH | \$213,390.00 |  |
|  |  |  | 1,403,017,797.00 |

## 002062

| CLIN 0017AB | KL | 118,250.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 118,250.00 |
| CLIN 0017AC | BZ | 190,000.00 |  |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021 AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |


| CLIN 0024 | LA | 13,508.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1.SECTION G - CONTRACT ADMINISTRATION DATA

## Accounting and Appropriation

Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 37,271,952.00$ from $\$ 1,628,358,149.81$ to $\$ 1,665,630,101.81$.

SUBCLIN 0017AA:
MF: 2112040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 37,271,952.00$ from $\$ 157,500,000.00$ to $\$ 194,771,952.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 37,271,952$ is distributed as follows and includes an increase in target cost of (\$ $\quad 18$ of facilities capital cost of money) and an increase in target incentive fee of hich is target cost less facilities capital cost money. (b)(4)


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph $c$., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding

| PRIOR | THIS MODIFICATION | CUMULATIVE TOTAL* |
| :---: | :---: | :---: |
| \$1,576,087,940 | \$ 0 | \$ 1,576,087,940 |
| $\square \square(4)(4)$ |  |  |
|  |  |  |
| \$ 1,403,017,797 | \$37,271,952 | \$ 1,440,289,749 |
| \$ 173,070,143 | (\$37,271,952) | \$ 135,798,191 |

* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00225 showing a summary of funding by ACRN through Modification P00226:

ACRN FUNDING
AA
440,100.00
AB
2,298,235.00
AC
17,832,987.00
AD
0.00


| KX | 60,000.00 |
| :---: | :---: |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |
| LG | 62,000.00 |
| LH | 400,000.00 |
| LJ | 7,476.00 |
| LK | \$281,575,897.00 |
| LL | \$173,798.00 |
| LM | \$1,410,376.00 |
| LN | \$630,061.00 |
| LP | \$83,200.00 |
| LQ | \$235,566.00 |
| LR | \$125,000.00 |
| LS | \$6,069,616.00 |
| LT | \$530,377.00 |
| LU | \$9,100,000.00 |
| LV | \$1,957,265.00 |
| LW | \$255,567.00 |
| LX | \$68,000.00 |
| LY | \$263,104,555.00 |
| LZ | \$1,751,384.00 |
| MA | \$2,982,442.00 |
| MB | \$375,000.00 |
| MC | \$2,283,481.00 |
| MD | \$8,573.00 |
| ME | \$0.00 |
| MF | \$194,771,952.00 |
| MG | \$6,262,095.00 |
| MH | \$213,390.00 |

3. The following is an update to Modification P00225 showing a summary of funding by CLIN by ACRN through Modification P00226:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
| CLIN 0003 | AF | 3,300,000.00 |  |
|  | , | $02068$ |  |


| CLIN 0003 | AG |
| :--- | :--- |
| CLIN 0003 | AH |
| CLIN 0003 | AM |
| CLIN 0003 | AN |
| CLIN 0003 | AP |
| CLIN 0003 | AS |
| CLIN 0003 | AT |
| CLIN 0003 | AW |
| CLIN 0003 | AY |

CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
BA
BB
BC
BD
BE

## BF

BG
BH
BL
BZ

CLIN 0007AA
BP

CLIN 0009AA
AQ
AV
BK
BM CLIN 0009AA CLIN 0009AA

CLIN 0009AB
CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB CLIN 0009AB

CLIN 0013
CLIN 0013
CLIN 0013

AU
AX AY

```
17,192,400.00
    700,000.00
17,045,000.00
            5,800.00
20,779,000.00
                0 . 0 0
    6,984,678.52
    100,000.00
    550,000.00
```

24,527,878.00
$146,000.00$
72,000.00
85,000.00
$100,000.00$
$100,000.00$
1,975,321.00
38,018,908.00
0.00
0.00


$10,199,288.50$

45,106.00
0.00

256,545.00
125,000.00
21,315.00

200,000.00
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00
9,000.00
869,034.00
$\begin{array}{r}94,288,100.52 \\ \hline\end{array}$

65,025,107.00


$$
10,199,288.50
$$

$\qquad$
447,966.00

7,970,000.00
3,396,000.00
0.00

| CLIN 0013 | AZ | 19,412,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0013 | BJ | 7,898,834.79 |  |
|  |  |  | 38,676,834.79 |
| CLIN 0017 | BW | 0.00 |  |
| CLIN 0017 | KM | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AA | BY | 3,880,000.00 |  |
| CLIN 0017AA | BX | 1,146,000.00 |  |
| CLIN 0017AA | BW | 84,896,852.00 |  |
| CLIN 0017AA | BZ | 0.00 |  |
| CLIN 0017AA | KM | 192,793,000.00 |  |
| CLIN 0017AA | KN | 0.00 |  |
| CLIN 0017AA | KQ | 66,151.00 |  |
| CLIN 0017AA | KS | 0.00 |  |
| CLIN 0017AA | KT | 386,204,200.00 |  |
| CLIN 0017AA | KU | 2,203,183.00 |  |
| CLIN 0017AA | KY | 0.00 |  |
| CLIN 0017AA | LC | 200,000.00 |  |
| CLIN 0017AA | LD | 7,943,648.00 |  |
| CLIN 0017AA | LE | 0.00 |  |
| CLIN 0017AA | LH | 400,000.00 |  |
| CLIN 0017AA | LJ | 7,476.00 |  |
| CLIN 0017AA | LK | 281,575,897.00 |  |
| CLIN 0017AA | LQ | 235,566.00 |  |
| CLIN 0017AA | LS | 6,069,616.00 |  |
| CLIN 0017AA | LT | 530,377.00 |  |
| CLIN 0017AA | LU | \$9,100,000.00 |  |
| CLIN 0017AA | LV | \$1,957,265.00 |  |
| CLIN 0017AA | LW | \$255,567.00 |  |
| CLIN 0017AA | LX | \$68,000.00 |  |
| CLIN 0017AA | LY | \$263,104,555:00 |  |
| CLIN 0017AA | MB | \$375,000.00 |  |
| CLIN 0017AA | MC | \$2,283,481.00 |  |
| CLIN 0017AA | MD | \$8,573.00 |  |
| CLIN 0017AA | ME | \$0.00 |  |
| CLIN 0017AA | MF | \$194,771,952.00 |  |
| CLIN 0017AA | MH | \$213,390.00 |  |
|  |  |  | 1,440,289,749.00 |
|  |  |  |  |
|  |  |  |  |
| CLIN 0017AB | KL | 118,250.00 |  |
|  |  |  | 118,250.00 |

## 002070

| CLIN 0017AC | BZ | 190,000.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021 AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
|  |  | 2071 |  |


| CLIN 0024 | LP | 83,200.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)

12. ACCOUNTING AND APPROPRIATION DATA (If required)

## 13. THISITEM APPLIES ONLY TO MODIFICATIONS OF OONTRACTSORDERS <br> IT MODIFES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A. THISCHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM I4 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM IOA.
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B),
$X$ C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: FAR 43.103(a)(3), Mulual Agyeement
D. OTHER (Specify type of modification and aurhority)
E. IMPORT ANT: Contractor $\square$ is not, $X$ is required to sign this document and return 1 copies to the issuing office.

I4. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modificalior Control Number:
To revise Seption H threntive FuesưUcture and Payment for OUN 0017 , Sysiem Development and Derronstrallon (SDD)." to docurment a fee penaly $\quad$ dua to a schedule delay for System Capablility Review (SCP) 1 and to revise Section J, "Performance hcentive Fee Oriterla/Evidence, to reflect the penaly.



Prescribed by CSA
FAR (48CFR) 53.243

## SUMMARY OF CHANGES

## 1.SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows:

## Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph c (2), is revised as follows:

a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of $\$ 1,576,087,940$ includes a target cost of $\quad$ which includes ? forilities capital cost of money) and a target incentive fee or which is farget cost less facilities capital cost of money.

## b. Cost Incentive.


(2) The maximum fee payable under SubCLIN 0017AA is of the target cost less facilities capital cost of money $\quad$ n amount equal to
(3) The minimum fee payable under SubCLIN 0017AA for the target cost less facilities capital cost of money mount equal to
(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio vermment Contractor for actual costs less than the target cost, and a ratio o Dovernment / Contractor for actual costs greater than the target cost range applied according to Paragraph $\mathrm{H}-19(\mathrm{c})(1)$.
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.


(2) An additional performance incentive fee pool of
(maximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:
(a) maximum) earned based on successful conduct of technical performance defined by SCR-1.
(b)
imam) earned based on successful conduct of technical performance defined by SCR-2.
(c) maximum) earned based on successful conduct of technical performance defined by SCR-3.
(d) maximum) earned based on successful conduct of technical performance defined by LUT.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section J attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is eared.
(3) For Earned Value and cost reporting purposes, the target cost value of $\$ 1,446,946,473$ will be used.

## 2. SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

## TITLE

Contract Security Classification Specification (DD Form 254), Revision 11 (Added per Modification P00187)
(DD Form 254 mailed via US Postal Service)

## b

JLENS Software Source Code Specifically Negotiated License, 04 Sep 08
License Number JLENS-SWLA-01
(Added per Modification P00166)
CLIN 0017:
JLENS System Development and Demonstration (SDD) Program Statement of Work (Revised by Incorporating CSDR Plans dated 20 Fer 2007 in Appeildix C per Modification P00136)

JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification P00187)

DATE
14 May 09
-
\# OF PAGES
11

JLENS System Development and Demonstration
Revised 09 Mar 10
36
(SDD) Program Statement of Work, Revision 2
(Added per Modification P00207)

## (b) (3) (A)

March 081

01 Dec 06
63

Revised 05 Apr 07
Revised 24 Oct 07

Revised 11 Jul 08

Revised 07 May 09

Revised 20 Mar 09
60

Contract Data Requirements List (DD Form 1423)
Exhibit A, Data Item Nos. B002 through B062 (less B014)
(Added per Modification P00187)
*Added statement below to address weekends/Holidays: (In Mod P00143)
*Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DD Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Government Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for resubmittal will begin on the next business day. Statement added in Mod P00143 on 24 Oct. 2007.

GFE/GFP/GFS List for SDD
Replaced with Rev. B List
**Add items below
For record-keeping purposes
(Per Mod P00143)
Replaced with Revision C List
(Per Modification P00183)
Replaced with Revision D List
(Per Modification P00207)

28 Nov 06
2
15 Oct 07
Revised 22 Oct 07

09 Mar 09
12

23 Feb 10
11
**Per the DCMA and $\quad$ Raytheon is authorized rent free use on a non-interference use of the equipment listed below for utilzation on JLENS Fire Control Radar Prime Contract DASG60-98-C0001 for the period from 19 April 2007 through 30 September 2011.

Hereby added in Mod P00148 for tracking purposes:
Originated in Basic Contract:
Government Furnished Equipment - Spiral $1 \quad 20$ Jun 03 1 List
(Spiral 1 Equipment Transferred to Government
25 Mar 07* 34 pages
Contract DASG60-00-C-0091, DD Form 1149 (attached) (Revised 21 Nov 07)* 34 pages
Gov't Technical POC:
(b)(6)

Ship to address:

> (b)(4)
*NOTE: Items 1-1060 transferred to Contract DASG60-00-C-0091 per revised GFE list dated 21 Nov 07 . Items 1061 - 1116 GFE items retained on Contract DASG60-98-C-0001 for Spiral 2 per GFE list dated 25 Mar 07.

JLENS Performance Specification, MIS-PRF-55628, Revision A
(Added by reference per Modification P00168)
Annex A to the JLENS Performance Specification,
MIS-PRF-55628, Revision A
(Added by reference per Modification P00168)

## JLENS SDD DD250 Plan

(Added per Modification P00207)

## Performance Incentive Fee Criteria/Evidence (Revised per Modification P00227)

CLINs 0023 and 00024
JLENS Simulation Support
SOW dated 28 January 2008
Simulation Support Tasks
(b)(3)(A)
(Added per Mod P00160)

## CLIN 0025

JLENS Integrated Fire Control Demonstration Program
Statement of Work, Revision 5
(Added per Modification P00211)
JLENS Integrated Fire Control Demonstration Program
Program and Technical Clarification Description, incorporated herein by reference

27 Jun 08
136

27 Jun 08

11 Dec 09

Undated
8

28 January 2008
2 pages

14 Sep 09
3

30 Mar 10 26
(Added per Modification P00211)

| Contract Data Requirements List (DD Form 1423) <br> Exhibit B, Data Items Nos. B001 through B004, with <br> Data Item Descriptions <br> (Added per Modification P00165) | 16 Oct 07 |  |
| :--- | :--- | :--- |
| Contract Data Requirements List (DD Form 1423), |  |  |

## CLIN 0027

| JLENS System Integration Lab (SIL) | Undated | 6 |
| :--- | :--- | :--- |
| Equipment List |  |  |
| (Added per Modification P00196) |  |  |
| Revision to System Integration Lab (SIL) | 02 Aug 10 | 6 |
| Equipment List <br> (Added per Modification P00217) |  |  |

(End of Summary of Changes)

## Performance Incentive Fee Criteria/Evidence

|  |  | \% | Criteria | Evidence |
| :---: | :---: | :---: | :---: | :---: |
|  |  |  | SQT/FVTs tied to VSRs .... <br> SCR Held on Schedule. Delivery of presentation material, meeting minutes, action items and attendees <br> 4 Scenarios sucessfully run in CMDS SIL and matched to contractor SIL results | VIS, VSR, Capability Matrix, Scenario results, Contractor SIL results, Analysis results CDRL B001 and B014 <br> Successful scenario results |
|  |  |  | SQT/FVTs tied to VSRs .... <br> SCR Held on Schedule. Delivery of presentation material, meeting minutes, action items and attendees <br> 4 Scenarios sucessfully run in CMDS SIL and matched to contractor SIL results | VIS, VSR, Capability Matrix, Scenario results, Contractor SIL results, Analysis results CDRL B001 and B014 <br> Successful scenario results |
|  |  |  | SQT/FVTs tied to VSRs .... <br> SCR Held on Schedule. Delivery of presentation material, meeting minutes, action items and attendees <br> 4 Scenarios sucessfully run in CMDS SIL and matched to contractor SIL results | VIS, VSR, Capability Matrix, Scenario results, Contractor SIL results, Analysis results CDRL B001 and B014 <br> Successful scenario results |
|  |  | 100\% | Training material complete and issues resolved prior to start of LUT | Training certificates, hard copies, functional check |

## System Capability 1

| 1 | 1. Applicable Verification Information Sheets (VIS) and Verification Summary Reports (VSRs) for the System and each Prime Item are complete. (5\%) <br> 2. Validate through analysis, test or demonstration applicable Orbit-level integrated functionality. (10\%) <br> 3. Applicable SW builds are integrated and functional in the contractor System Integration Lab (SIL) and approved scenarios have been successfully run in the contractor SIL.(80\%) <br> 4. Supporting analysis which predicts successful test | 1. Applicable VISs* and completed VSRs are receipted by the JPO NLT 30 days prior to the upcoming SCR. In cases where a completed VSR is not available, the test artifacts will be receipted by the JPO NLT 30 days prior to the upcomng SCR. <br> 2. Capability Matrix Documented showing which requirements are to be deomstrate during the review or test. <br> 3a. Scenario results demonstrate the successful inplementation of applicable functionality and key requirements related to the upcoming SCR. <br> 3b. SIL results receipted by the JPO. <br> 4. Analysis results are complete and receipted by |
| :---: | :---: | :---: |
|  | 1. SCR is held NLT the contract IMS date IAW CDRL BOO1 and B014. | SCR presentation material, meeting minutes, action items and attendees. |
|  | 1.4 Scenarios are run the the CMDS SIL and have been successfully matched to scenarios that have been run the the contractor SIL. | 1. Scenario results deomnstrate the successful implementation of the simulation scenarios in the CMDS SIL with comparable results to the contractor SIL. |

## System Capability 2



## System Capability 3



## LUT IFC

|  | \% | Criteria | Evidence | Notes |
| :---: | :---: | :---: | :---: | :---: |
|  |  | Ah schoduled training classes have been conductad | Training certificates issued to Soldiors |  |
|  |  | UETP is In place and operational on the system LAW schrodule | Functional check |  |
|  |  | Embedded Trainling acenario's are generated and the Soldiers have been trained for using thom | Functional check |  |
|  |  | An agreed upon lise of LRU replacements is in place and the Soldiers have been trained on them | Hard copy of approved llet |  |
|  |  | All lasues found in the proceeding Force Development Exercise (FDE) have been resolved | FDE After Action Roview (AAR) and actions taken to addroess each issue |  |

(b)(3)(A)(i)\&Title 10 Sec 130
(a) (b)
(b)(3)(A)(i)\&Title $10 \operatorname{Sec} 130$
(a)(b)
SIL Comparison

(b)(3)(A)(i)\&Title $10 \operatorname{Sec} 130(a)(b)$
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title $10 \operatorname{Sec} 130(a)(b)$
002085


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 732,282.74$ from $\$ 1,665,630,101.81$ to $\$ 1,666,362,384.55$.

SUBCLIN 0017AA:

LY: 2102040 5L 5L68 P172419E555L 255Y 4M0J730000 S01021 4M0J730000/04MJLE/4M5 was increased by $\$ 732,282.74$ from $\$ 263,104,555.00$ to $\$ 263,836,837.74$

Target Cost, Target Fee, and Total for the above increase of $\$ 732,282.74$ is distributed as follows and includes an increase in target cost of facilities capital cost of money) and an increase in target incentive fee of target cost less facilities capital cost of money.

| Target Cost |  |  |
| :--- | :--- | :--- |
| Target Fee |  |  |
| Total | $\$ 732,282.74$ | (b) |
|  |  | (4) $(4)$ |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph $\mathbf{c}$., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00226 showing a summary of funding by ACRN through Modification P00228:

ACRN FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |


| AD | 0.00 |
| :---: | :---: |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK | 85,000.00 |
| AL | 45,000.00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975;321.00 |
| BH | 38,018,908.00 |
| BJ | 7,898,834.79 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |

## 002088

| KW | $20,000.00$ |
| :--- | ---: |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 263,836,837.74$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 90.00$ |
| MF | $\$ 9,771,952.00$ |
| MG | $\$ 213,390.00$ |
| MH |  |
|  |  |

3. The following is an update to Modification P00226 showing a summary of funding by CLIN by ACRN through Modification P00228:

| CLIN | ACRN | FUNDING AMT | CLIN TOTAL |
| :---: | :---: | :---: | :---: |
| CLIN 0001 | AA | 440,100.00 |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | 440,100.00 |
| CLIN 0003 | AB | 2,298,235.00 |  |
| CLIN 0003 | AC | 17,832,987.00 |  |
| CLIN 0003 | AD | 0.00 |  |
| CLIN 0003 | AE | 7,500,000.00 |  |
|  |  | $02089$ |  |


| CLIN 0003 | AF | 3,300,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0003 | AG | 17,192,400.00 |  |
| CLIN 0003 | AH | 700,000.00 |  |
| CLIN 0003 | AM | 17,045,000.00 |  |
| CLIN 0003 | AN | 5,800.00 |  |
| CLIN 0003 | AP | 20,779,000.00 |  |
| CLIN 0003 | AS | 0.00 |  |
| CLIN 0003 | AT | 6,984,678.52 |  |
| CLIN 0003 | AW | 100,000.00 |  |
| CLIN 0003 | AY | 550,000.00 |  |
|  |  |  | 94,288,100.52 |
| CLIN 0005 | BA | 24,527,878.00 |  |
| CLIN 0005 | BB | 146,000.00 |  |
| CLIN 0005 | BC | 72,000.00 |  |
| CLIN 0005 | BD | 85,000.00 |  |
| CLIN 0005 | BE | 100,000.00 |  |
| CLIN 0005 | BF | 100,000.00 |  |
| CLIN 0005 | BG | 1,975,321.00 |  |
| CLIN 0005 | BH | 38,018,908.00 |  |
| CLIN 0005 | BL | 0.00 |  |
| CLIN 0005 | BZ | 0.00 |  |
|  |  |  | 65,025,107.00 |
| CLIN 0007AA | BP | 10,199,288.50 |  |
|  |  |  | 10,199,288.50 |
| CLIN 0009AA | AQ | 45,106.00 |  |
| CLIN 0009AA | AV | 0.00 |  |
| CLIN 0009AA | BK | 256,545.00 |  |
| CLIN 0009AA | BM | 125,000.00 |  |
| CLIN 0009AA | BN | 21,315.00 |  |
|  |  |  | 447,966.00 |
| CLIN 0009AB | AJ | 200,000.00 |  |
| CLIN 0009AB | AK | 85,000.00 |  |
| CLIN 0009AB | AL | 45,000.00 |  |
| CLIN 0009AB | AQ | 59,894.00 |  |
| CLIN 0009AB | AR | 35,000.00 |  |
| CLIN 0009AB | BK | 3,455.00 |  |
| CLIN 0009AB | BN | 81,685.00 |  |
| CLIN 0009AB | BU | 350,000.00 |  |
| CLIN 0009AB | BV | 9,000.00 |  |
|  |  |  | 869,034.00 |
| CLIN 0013 | AU | 7,970,000.00 |  |
| CLIN 0013 | AX | 3,396,000.00 |  |
|  |  | $22090$ |  |

CLIN 0013 AY CLIN 0013 AZ CLIN 0013 BJ
0.00
$19,412,000.00$ 7,898,834.79 $\qquad$

| CLIN 0017 | BW |
| :--- | :--- |
| CLIN 0017 | KM |

0.00
0.00 $\qquad$

3,880,000.00
1,146,000.00
84,896,852.00
0.00

192,793,000.00
0.00
$66,151.00$
0.00

386,204,200.00
2,203,183.00
0.00

200,000.00
7,943,648.00
0.00

400,000.00
7,476.00
281,575,897.00
235,566.00
6,069,616.00
530,377.00
$\$ 9,100,000.00$
\$1,957,265.00 $\qquad$
$\$ 255,567.00$
$\$ 68,000.00$
$\mathbf{\$ 2 6 3 , 8 3 6 , 8 3 7 . 7 4}$
$\$ 375,000.00$

$\$ 2,283,481.00$ | $\overline{=}$ |
| :--- |
| $=$ |

$\$ 8,573.00$
$\$ 0.00$
\$194,771,952.00
$\$ 213,390.00$
$\square$
$\qquad$

$\qquad$
$1,441,022,031.74$

| CLIN 0017AC | BZ | 190,000.00 | 118,250.00 |
| :---: | :---: | :---: | :---: |
|  |  |  |  |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660:00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021 AB | KY | 0.00 |  |
|  |  |  | 0.00 |
|  | $\mathbf{K Z}$ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
|  |  | $2092$ |  |


| CLIN 0024 | KW | 20,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)

## 002093

## AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

| I.CONTRACTID CODE | PAGE OF PAGES |  |
| :---: | :---: | :---: |
| $V$ | 1 | 5 |





Except as provided herein, all series and conditions ofibe document referenced in ltem9A or IOA, as hermoform changed, romanians unchanged and in fall force and elect.


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

## TITLE

Contract Security Classification Specification (DD Form 254), Revision 11 (Added per Modification P00187) (DD Form 254 mailed via US Postal Service)

## DATE

14 May 09
\#OF PAGES
11

JLENS Software Source Code Specifically Negotiated License, 04 Sep 08
License Number JLENS-SWLA-01
(Added per Modification P00166)

## CLIN 0017:

JLENS System Development and Demonstration
30 Nov 06 -
Revised 20 Feb 07
Incorporating CSDR Plans dated 20 Febr 2007 in
Appendix C per Modification P00136)
JLENS System Development and Demonstration
(SDD) Program Statement of Work
(Added per Modification P00187)
JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 2
(Added per Modification P00207)


Contract Data Requirements List (DD Form 1423)
01 Dec 06
Exhibit A with Distribution List \& Data Item
Nos. B001 through B062
(Replace Data Item Nos. B026 and B027, only
Revised 05 Apr 07
Per Modification P00136)
(Replace Data Item Nos. B048 and B049, only
Revised 24 Oct 07
Per Modification P00143 \& to add statement in
Section A of Modification P00143)
(Replace Data Item No. B033 only, per $\quad$ Revised $11 \mathrm{Jul} 08 \quad 1$
Modification P00161)
Contract Data Requirements List (DD Form 1423)
Revised 07 May 09
2
Exhibit A, Data Item Nos. B001 and B014
(Added per Modification P00187)
Contract Data Requirements List (DD Form 1423)
Revised 20 Mar 09
60
Exhibit A, Data Item Nos. B002 through B062 (less B014 )
(Added per Modification P00187)
*Added statement below to address weekends/Holidays: (In Mod P00143)
*Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DD Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Government Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for resubmittal will begin on the next business day. Statement added in Mod P00143 on 24 Oct. 2007.

GFE/GFP/GFS List for SDD
Replaced with Rev. B List
**Add items below
For record-keeping purposes
(Per Mod P00143)
Replaced with Revision C List
(Per Modification P00183)
Replaced with Revision D List
(Per Modification P00207)

28 Nov $06 \quad 2$
15 Oct $07 \quad 6$
Revised 22 Oct 07

09 Mar $09 \quad 12$
23 Feb $10 \quad 11$
**Per the DCMA and Raytheon is authorized rent free use on a non-interference use of (b)(4) the equipment listed below for uthization on JLENS Fire Control Radar Prime Contract DASG60-98-C0001 for the period from 19 April 2007 through 30 September 2011.

Hereby added in Mod P00148 for tracking purposes:
Originated in Basic Contract:
Government Furnished Equipment - Spiral 1
(Spiral 1 Equipment Transferred to Government
Contract DASG60-00-C-0091, DD Form 1149 (attached) (Revised 21 Nov 07)* 34 pages
Gov't Technical POC:
Ship to address:

(b)(4)
*NOTE: Items 1-1060 transferred to Contract DASG60-00-C-0091 per revised GFE list dated 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98-C-0001 for Spiral 2 per GFE list dated 25 Mar 07.

JLENS Performance Specification, MIS-PRF-55628,
27 Jun 08
(Added by reference per Modification P00168)
Annex A to the JLENS Performance Specification, MIS-PRF-55628, Revision A
(Added by reference per Modification P00168)
JLENS SDD DD250 Plan 11 Dec 09 ..... 5
(Added per Modification P.00207)
Performance Incentive Fee Criteria/Evidence Undated
(Revised per Modification P00227)
Engineering Change Proposal (ECP) MI-N3893, 15 Nov 10 Revision 2, CDRL B039-005b
Engineering Change Proposal (ECP) MI-N3894,CDRL B039-006
Engineering Change Proposal (ECP) MI-N3895, CDRL B039-007
CLINs 0023 and 00024
JLENS Simulation Support
SOW dated 28 January 2008
Simulation Support Tasks
(Added per Mod P00160)
CLIN 0025
JLENS Integrated Fire Control Demonstration Program ..... $14 \operatorname{Sep} 09$
Statement of Work, Revision 5
(Added per Modification P00211)
JLENS Integrated Fire Control Demonstration Program30 Mar 10

Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211)
Contract Data Requirements List (DD Form 1423)16 Oct 07
Exhibit B, Data Items Nos. B001 through B004, with
Data Item Descriptions
(Added per Modification P00165)
Contract Data Requirements List (DD Form 1423),16 Jun 106
CLIN 0028, Exhibit B, Data Item Nos. B001 through B006
(Added per Modification P00211)
CLIN 0027
JLENS System Integration Lab (SIL)
Undated6
Equipment List
(Added per Modification P00196)
Revision to System Integration Lab (SIL)02 Aug 106818 Aug 10

Equipment List
(Added per Modification P00217)
(End of Summary of Changes)

002098

JOINT LAND ATTACK CRUISE MISSILE DEFENSE ELEVATED NEITED SENSOR (JLENS)

ECP Mi-N3893
CDRL B039-005
Rev R2
CAGE Code 05716
November 15, 2010
In Accardanca with:
Gontract No. DASGpo-98-C-D001
Coniract Llise litem Nimbers 0017
Prepanad tyy:
Rayitheon Compary
950 Lowoll Strees
Andorver, MA 01a10
DISTRIBUTIGN STATEMENT F , Further tissemanation only as diractan hy the Gruke Miselle Defenge Systems Projact Ohfite, SFAE-MSLS-CMDS-PE-CM. Radatone Araenal, AL 35898-5000, 24 March 2060.

WARM|NG - This danument contains technical dala whase expori ls resiricted by the Arms Export Gantrol Ack \{Title 22, U.S.C., Sec 2751 et saq.\} ar the Export Adminisiration Act of 197g, as ammedan, Titlo 60. U.3.C., app 2401 at Egq. Vlolation of lhese expont lawz are subject to savare criminal peralties. Disseminate in accardance with provisions of DDD Directive 5289.25.

DESTRUCTION NOTICE - For classfied documants, follow the procoduras in DOD 5220.22-W, National Induttrlal Siecurity Frogram Opersting Manual (NISPOBI), Chapter S, Section T, or DOD S210. i-R, Information Securily Eragrann Regulation, Chapier IX. Far unclassilad, limitad documente, desiroy fuy any methad that will prevent disciosure of contents or recansiructian of the document.

Cupyright ©20L0 Rayaheon Cumpuny
This data was developad pursuant to Contract Number DASGB0-98-G-n001 with the US Govermmant. The US Governmant's rights in and to this copyrightad data are as apectiod in


## Raytheon Praprietary

CAGE Code O5316
November 15, 2010
ECP MI-N38日3 Rev. R2

## CHAYGE RECORD PAGE

| Revision | Date | Affacted Pages | Autiorized By ${ }^{\text {j }}$ | Explanation of cirange |
| :---: | :---: | :---: | :---: | :---: |
| - | $8 / 2152010$ | A] |  | Original Document |
| R1 | あ30/20ㅁ | All |  | Originas Document |
| R2 | 11/15/2010 | All |  | Original Document |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

(b)(6)

Approval Signatures

(b) (6)
(b) $(6)$
(b) $(10)$

(b) $(6)$
(b) $(6)$


## Table of Contents

## Page

1
ECP MI-N3893 Rev. R2 for H377785 CPG PIDS Rev. K.

CACE Code 05716
Novambar 15, 2010
ECP MI-N3BGs Rey, R2


CAGE CDA日 05716
November 1S, 2010 ECP M1AN3 393 Rev. R2

| ENEINEERING CHANCE PROPOSAL [EGP/ PAGE 2 |  | Forth Appargwer <br>  |
| :---: | :---: | :---: |
|  <br>  <br>  <br>  PLEASE DO ROT RETURN YOUR COMPLETED FORNE RETURN CORTPLETED FOR筩 TO THE GQVERNAENT THE CONTRACT I PROCEIRING ACTIVITY NUHERER LE FORM 10:2R |  <br>  un Of mens ind Repers, 1215 I fivnan ometig in C е man <br> HER OF THESE ADDRESSEES, CONIRACTING OFFIGER FQR ITEM 2 OF THE COMPLEEEDOD |  <br>  Bact 1209 Atraton Wh $23808-1302$ <br>  |
|  |  |  |
| 2I UTHER BYSTEMS ANTGCTID Mana |  |  |
|  <br>  |  |  |
|  Nan: |  |  |
|  traparan iflistor Thining |  |  |
|  <br>  |  |  |
|  hen* |  |  |
|  Nant |  |  |
|  4nuse |  |  |
| DD Ferm 16ar21, APR 92 frompudar Gorsarateds P | gatbang are amaciole. |  |


41. ARIERTLTESGUITICM6
42. DEVELOMDENTAL BTATLS
43. RECDMMENOKTIONS FOR RETRDFI

|  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 2. <br> ginganceation NA |  | EDEGOT | d.07/K明 |  |  |
|  |  |  |  |  | 48. CUT DF Eivinct TmE |
| ERPDE $\overline{\mathrm{Na}}$ | $\int_{\mathrm{NG}}^{\mathrm{WHFH}}$ | AFTER TE FOLLINEIS cithates MA |  |  | NH |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  | D. RETMJEAT WA |  |

CAGE Code 057 is
Navember 15, 2010 ECP ML-N3sg3 Rew. R2

## ENGINEERING CHÁNGE PROPOSAL (ECP), PAGE 4 Not Applivable Fompappovid <br> ONBE MO DFO4-078B




FLEASE DOEOT RETURN YOUM COMAPLEYED FORN TO a|YHEN OF TMESE ADDRESSES, RETUXM
 PROCUFUNG ACTMITY NUHBER LISTED IN ITEM 2 OF THE COMPLETED DD FORM 1 SSI


| FAETOR |  |  |  |  |  | Oher CosterSanngs ta theGovarnment(O |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Noh-Recumint(a) | RECJRAING |  |  | ICetal (降) |  |
|  |  | $\begin{aligned} & \operatorname{LnT} \\ & \text { (b) } \end{aligned}$ | Quantioy (c) | $\begin{aligned} & \text { TDKal harral } \\ & \text { (d) } \end{aligned}$ |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| b. REENDFIT COgT |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| syysters <br>  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| $\qquad$ |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| U1TETIM AFYEPGETMOKI |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| $\qquad$ |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  PAOGRAMEDDOCUTENTATION |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| (1) OTHER COSTEASAVMGE |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| 17. |  |  |  |  |  |  |
| \$. CDORDINATION OF CNANGES WITH OTHER CDNTRACTORS |  |  |  |  | . | Nons |
| 9. COORDIMATIOR CHANEES 日Y GOVERNMENT |  |  |  |  | ; | T00\% |
| h. ESTIMATED NET TGTAL COSTSMSHMNGS |  |  |  |  | i | Nomo |

CAGE Code 05716
November 15, 2010 ECP M1-N38B3 Rev. R2

## ENGINEERING CHANGE PRDPOSAL (ECPP) PAGE 5 Not Applicable

fomn Apprevad OMA No. TRA-Otas





CAGE Gade 05716
Nowernber 15, 2010
ECP M1-N3Ag3 Rev. R2


DD Form 165215, APR 92
fCompular GenanaladJ


CASE Code 05716
Nowamber 15. 2010 ECP MI-N3 2 gs Rev. R2


## Notice of Ravision (NOR)

## Sheot 1 of 1


(b) (3) (A)
(i) \&Title

10 Sec
130 (a)


| 14. THIE 3ECJION POR GOVERHMENT USE ONLY |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| 8. (X ONE) |  <br>  <br>  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| b. RCTHTTY AUTHORIEE TO APFROVE CHANGE FOR GOVERNMENT |  |  |  |  |
| 디ITLLEE |  | E. EIGtature |  | 1. DATE SIENED \{TYMADOS |
| 15. a. ACTIMTY ACCOMPLEHING REVISION |  |  |  | c DATE SIGNED (YTWhDDI) |


| Titag of Document | Pror Ne. |
| :---: | :---: |
|  |  |
|  | Dacumem Na <br> H377785 |

# JOINT LAND ATTACK CRUISE MISSILE DEFENSE ELEVATED NETTED SENSOR (JLENS) 

ECP MI-N3894<br>CDRL B039-006<br>Rev -<br>CAGE Code 05716<br>August 18, 2010

In Accordance vath:
Contract No. DAS 960 -80-C-0001
Comiract Lina Ibem Numbere 0017
Prapared by:
Raytheon Company
350 Loweld \$irset
Andover, MA 01810
DISTRIBUTION STATEMENT F - Further diasemination only as directed by the Gruise wissile Defense Systams Projact Office, SFAE-MSLS-CMDS-PE-CMF. Redstona Arsenal, AL 35898-5000, 24 March 2000.

WARNING - This dacument mantains fechnical data whose export is restrictad by the Artus Export Control Act (TItie 22, U.s.C., Sec 2751 et छeq.) or ithe Export Administration Act of 187s, at amended, Tifle 50 , U.S.C., app 2401 at seq. Vindation of these export laws are subjoct to severs cyiminal ponaliies. Dlsseminate In aceardance with provielons of DOD Directlve 5230.35.

DESTRUCTION NOTICE - For classified documents, follow the proceduras in DOD 5220.22-M, Nationel Industrial Becurlty Pragram Operating Manual (NISPOM), Chaptar 5, Section 7, or GOD $\$ 200.1$-R, Information Security Program Regulation, Chapter IX. For unclassiflad, Imited documente, tiestroy by any mathod that will prevent disclosure of centents or recorsatruction of the dacument.

Copyr)
This data was develeped persuant to Contract Number DASG60-98-G-0u02 with the US Government. The US Governmenf's rights in and to this copyrightad data are as specifled in
DFARS 252.227-7013 (a) (15) \& (b) (1) Nov 1995 which was made a part of the above coniract.


Approval Signatures

(b)

(b) $(b)$

(h) (6)

# Raytheon Proprietary 

## Table of Contents

Page
1

Description
ECP ${ }^{\text {all-N3B84 }}$ for H137778S CPA PIDS Rev. K


CPG fics Rey, K updatea ke IFC Dame
20. HEED PDAEMANGE



DD Form 1gSR, $A$
(b)(6)

Faytheon Proprietary

## ENGINEERING CHANGE PROPOSAL [ECP), PAGE 2

EFFEGTS ON FUNCTIQNALAILQCATED CONFIGURATION DOCUMENTATION

30. DCDNFIGURZTTON MEMG AFFECTEO
trit Pifane lbam
31. EFFECTE IN FERFCWMRNRE AL,



Nor 4
32. EFFECTIG वIN GCONFIGURATIUN ITEM EPECIRICAEIOLS

H. पEVELOPMENTAR RERUIREMEKTA AKDgTATU日


49n4


DD Form 1892M, APR 92 (Carnoudor Gangraded) Previnuts efltions arts absolele.

## Raytheon Proprietary (b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

CABE Code 05716
August 18, 2010

## ENGINEERING CHANGE PROPOSAL (ECP), PAGE 3

Fome Approved Ont Mo. 0784-01ES

41. ALTERNATE SOUITINM

NA
42. DEVELOPMENTALETATUS

NA

4R RECOMMENUATIONA FOR FETROFTT
NA

|  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1. <br> oramgrtation <br> NA | LI MTEAMEDIATE | EDA | $\begin{aligned} & \text { A GIERR } \\ & \text { WA } \end{aligned}$ |  |  |
|  |  |  |  |  ENAMEERMG NEDUIREM | 22 OUTOF SEXVICE TINE |
| $\int_{\text {EA }}^{\text {EGRE }}$ | $\begin{aligned} & \mathrm{wnith} \\ & \mathrm{Nan} \end{aligned}$ |  | LLOWIMO | $\square \mathrm{Yeg}$ | Nh |
|  MR |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  | D. RE\MCVT सम |  |

CAGE Code 05715
August 18, 2010
ECP M|-N3894 Rew



August 18, 2010 ECP Mi-N3B94 Rev-


Raythean Proprietary


(b)(3)(A)(i)\&Title

Sec $130(\mathrm{a})(\mathrm{b})$


PROD, EFF,



| 14. THIS SECTION FOR GOWERNWEMT UEE ONLY |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| a. $\times$ X ONE | [1] Exigling dacurinent supplemented by his NixR <br>  <br>  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| b, ACTTHTY ALTHORIZED TO APPROVE GHANCE POR <br>  |  |  |  |  |
| d. TITLE |  | E. SIGMATURE |  | C. DATE SIGNED YYMADOT |
| 15. A. ACTWTTY ACCOAPLISHINH REWISION |  | D. R | PLETED $\{$ Pialaturt | E. GATE SIGNED (rrumbic) |


| Thle di Dactument | NOR NO |
| :---: | :---: |
|  |  |
|  | Datument Mas. H377785 |

- 
- 

002129

# JOINT LAND ATTACK CRUISE MISSILE DEFENSE ELEVATED NETTED SENSOR (JLENS) 

## ECP MI-N3895

CDRL B039-007
Rev-
CAGE Code 05716
September 28, 2010

In Ancordance with:
Contract No. OASCeO.98-C-0001
Cantract Line Item Numbers 0017
Prepared by:
Raytheon Company
350 Lowell Sireet
Andowar, MA 01810
D|STRIBUTLON STATEMENT F - Further diasemination only as directed by the Cruise Missile Defanse Systems Project Office, SFAE-MSLS-CMDS.PE-CM, Radatone Arsanal, AL 3599B-5000, 24 March 2000.

WARNING - Thig documant contains technical data whose export is restricted by the Anms Export Control Abt (Titie 22, U.S.C., Sac 2751 ot seq.) or ihe Export Admlnistration Act of 1979, as amended, Tifla 50, U.S.C., app 2401 et seq. Violation of thase axport laws are subjact to severe eriminat penalias. DEsaeminata in accordance with provislons of DOD Dlrectlve 5230.25.

DESTRUCTION NOTIGE - For classified documenta, follow the procerluras in DOD 6220.22-M, Natlonal Industrial Security Program Oparating Manual (NISPON), Chapter E, Sestion 7, or DOD E200.1-R, Information Security Frogram Regulation, Chapter IX. For unclassifled, Ilmited documents, destroy by any method that will prevant disclosure of contents or reconstruction of the document.

Copyright © 2010 Ruytheon Company
This data was devalopad pursuant to Contrat Number DASG60-98-C-0001 with the US Govarnment. The US Government's rights In and to thls copyrighted data are as specified in DFARS $252.227-7013$ ( 3 ( 15 ) \& (b) (1) Nov 1995 which was made a part of the atove contract.

## Raytheon Proprietary

CAGE Code 0.5716
September 2B, 2010 ECP M-N3895 Rev
CHANGE RECORD PAGE

| Revision | Dat: | Affected Pages | Authurlzad By | Explanation of Change |
| :---: | :---: | :---: | :---: | :---: |
| - | g/za/z010 | All |  |  |
|  |  |  |  | Original Document |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |



Raytheon Proprietary

# Robytheon Propiltatary 

CAGE Code 05716 Septernber 28, 2010 ECP MIFN3BS5 Rev.

Table of Contents
Page
Descruption
1 ECP minkans for H377\%s Cry Pids Rev, K

Raytheon Propriatary
GAGE Code 05716 Espiembar de, 2010 ECP MI-N98es Ren-



FIEASE DO NOT RETURN YOUR COMPLETED FORH TO EITHER OF THESE ADDRESSES,

EFFECTS ON FUNCTIONALALLDCATED CONFIGURATION DÖCUMENTATION
2. CTHER Shtitera AFFECTED Nans


CAGE Code 06716
Septemfer 26， 2010 ECP M1－N389G Rey．

## ENGINEERING CHANGE PROPOSAL（ECP），PAGE 3





 FETURN COMPLETED FORM TO THE GOVERNMENT FEUING CONTRAGTING OFFIGER FOR THE GONTRACT I PROCLRING ACTMTY NU日BER LISTEBINITEM 2 OFTHE COMFLETED DD FORM 1693．

EFFECTS ON PRODUCT COMFIGURATION DOCUMENTATION，LOGISTICB ARMO OPERATIONS NOT APDIIOZBlo

| （ ${ }^{(x)}$ | FACTOA | ENCL |  | （x］ | FACTOS | ENCL． | PNR． |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\because$ $\therefore$ $\therefore$ |  DONFGURATIDN DOEHNENTATMMCR EONTHAET | $\because \cdot *$ |  |  |  |  |  |
|  | E．PEPEORMANCE |  |  |  | 6．可狺年 |  |  |
|  |  |  |  |  | D．SURYNADMETY |  |  |
|  | t．WEIGNT WhDrement caber equamenp |  |  |  | 6．RELTULIT |  |  |
|  | a．COAL JECHNICAL DHATA |  |  |  | C，Meaminatay |  |  |
|  | Q．NOKENCLITUAE |  |  |  | E BENMCELIFE |  |  |
|  |  |  |  |  |  |  |  |
| $\because$ | SB．EFPECT ONINTENRAIETO LOCSTICS |  |  |  | 6．ELEMTRDMAGNETICIMTERFEREWCE |  |  |
| － | sunpors illst |  |  |  | h．ACENATMAMSCNEOLIS |  |  |
|  | D．ILSPLANS |  |  |  | 1．CAIVKM SVGIE PGWY FauLide |  |  |
|  | D．FA｜NTLMAKCEE CONCEPT，PLANS ANP |  |  |  | Imeng |  |  |
|  | PRGCEDURES |  |  |  | LINTERGPERSBILIT |  |  |
|  |  |  |  |  |  |  |  |
|  | 4．INTERIM SUPP（ORT PAOGRA）MS |  |  |  |  |  |  |
|  | B．SPARES AND KEMAIR PANT |  |  | $\because$ | 44 0w je conmperatiang | －rnicot 4 | 1，\％\％m |
|  |  |  |  |  | a dinemptar |  |  |
|  | D．FबCIITIEIES |  |  |  | b पTHEAAFFECTECIEQUIPMENTSGESEFP |  |  |
|  | h．SUPPORI ECUIPMENI |  |  |  | a PHPGCh CONSTMAT8 |  |  |
|  | 1．EPORAYOR YRAINING |  |  |  | 4 COMFITER PROGRAMS A＊ND |  |  |
|  |  |  |  |  | Rescurces |  |  |
|  | K．MSINTENANOE 7RALUEM |  |  |  | S．EETCAK OF OTHER ECDIFMENY |  |  |
|  |  |  |  |  |  |  |  |
|  | In CONTMACT MANIENNNLE |  |  |  | Q Warishirimurkyle |  |  |
|  |  |  |  |  | H．PARTSCDNINTL |  |  |
|  |  |  |  |  | IHFICMCLEOSIS |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

## 49．ALTERNATE SOLIMONS

MA

42．DEVELOPMENTAL 9TATUS
INA

## 4．RECOMMENDATKONE FOR RETADFIT

Ma

| Ch Wakxali | T11 | ITp1 |  | 40．WORN HOUMS TO CONDUUCT SYSTEM TRAIS MFYER REIEOFIT MA |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 9. <br> ORGANIZATIEM NS | b．Uriemincuate Ha |  | ब．वामघ 3 H |  |  |
| A THISCHANGE MLST EE AOCOMPISSECO |  |  |  | 48．TBCOMRADIDEFEDEERVICE <br>  |  |
| egrora | $\mathrm{MaH}_{\text {Mit }}$ | AFFR TH F FDUCNMNG chamater na |  |  | NA |
|  $\mathrm{N} / \mathrm{H}$ |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  | D．RESRCPIT NR |  |



GAGE Code 05716
Seplember 29， 2010
ECP MI－N3BB5 Rev－
ENGINEERING CHANGE PROPOSAL（ECP），PAGE 4 Not Applicable
Form Approved
 maj
 and lathe atioc a



 31．Eatiokimo

| PAGTOR | COSTIEAVINGSUNDER CONIRACT |  |  |  |  | OWhar Cosas＇ Sivings to the Gavermmond 10 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Narl Resurting ［a） | FECURRINĠ |  |  | Total （a） |  |
|  |  | Bnil <br> （b） | Quatrilly （ 5 |  |  |  |
| 8．PRCIUNGTION COSTBKMNE\％ |  |  |  |  |  |  |
| （1）DOMFIGUAKTIONITEMCLCA |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| （1）PECSAL FRETOMY ROCun |  |  |  |  |  |  |
| 10）SCRAP |  |  |  |  |  |  |
| evition <br>  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| B．REIERFIT COST |  | ： | $\cdots$ | \％ |  | 20， |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| （1）Mir Phocs Jmitima |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| $\qquad$ <br>  |  |  |  |  |  |  |
|  | $\cdots$ | ：$:$ | ？ | 为， | ，2\％… |  |
| CH TETNK AFTER KETRCFT |  |  |  |  |  |  |
| 1101 MCOITCAICOICP GPEAPP |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| c．NTGGRTED LGGIETICE BUPPORT EOgTBEAVINES | $\therefore$ ． |  | $\therefore$ ： |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| ［5） |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
| ［1］COTHTER PROGRAMAMDCUMENTATIOM |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  | $\cdots$ | ，．＊ |  |  |  |
| 15．EUBIUTAL DNIMEA | $\because$ | \％ | ， | $\cdots$ |  |  |
| F．COORPINATHOM OF CMANGES MTH CTHER CONIRACTORA |  | $\because \frac{1}{3}$ |  |  |  | Norse |
| 日－COORDINATICN CHANAES BY GOYERNMENT |  | $\because \hat{}$ |  |  | 电 | N＊＊ |
| h．ESTIMATED MET TGY骨 COSTEISAYIGS |  |  | 为 | 为 |  | Name |

## ENGINEERING CHANGE PROPOSAL (ECP), PAGE 5 Not Applicable





PLEAEE DO NOT REIURN YOGR CONPLETED FOFM TO EITHBR OF THESE ADDRES\&ES, RETURN
 COMPLETED FORA TO THE GOVEANMENT IESUNZG CONIRACTNG OFFICER FOR THE ZONTFACTI




GAGE Code 05718
Segtamber 28, 2010 ECP MI-N3895 Rev-


DD Form 1492i6, AFR 92
Compsufar Gonserstody
Pravious entilans aro odisolata.


## Notice of Revision (NOR)

Sheet 1 of 39

(b)(3)(A)(i)\&Title 10

Additional Changes balow.
Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

002142
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

## 002143


(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

002144
Notice of Revision (NOR)

## Change Build Allacalion aecording to tabla below.

(b)(3)(A)
(i)\&Title
10 Sec 130
(a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec

130 (a)(b)

(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

(b)(3)(A)
(i) \&Title 10

Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)


(b)(3)(A)(i)\&Title
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130
(a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
$\square$

(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130
(a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

002157

(b)(3)(A)
(i) \&Title 10

Sec 130 (a)(b)
(b)(3)(A)
(i) \& Title 10 Sec 130 (a)(b)
(b)(3)(A)
(i) \& Title 10 Sec 130 (a)(b)


(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)
(b)(3)(A) (i) \&Title 10 Sec 130 (a)
(b)
(b)(3)(A)
(i) \&Title 10 Sec 130 (a)(b)
(b)(3)(A)
(i) \& Title 10 Sec 130 (a)(b)
Notice of Reyislon (NOR) continued
002163
(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)

(b)(3)(A)
(i)\&Title 10

Sec 130 (a)
(b)
(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)

002166
(b)(3)(A)
(i) \& Title 10 Sec

130 (a)(b)

(b)(3)(A)(i)\&Title

002168
(b)(3)(A)
(i) \&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10

Sec 130 (a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)
(b)(3)(A)(i)\&Title $10 \operatorname{Sec} 130(a)(b)$
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

## Shoet 31 of 89

(b)(3)(A) (i) \&Title 10 Sec 130
(a)(b)
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)


002174
(b)(3)(A)
(i) \& Title 10 Sec
(b)(3)(A)(i)\&Title 10 Sec $130(a)(b)$
(b)(3)(A)(i)\&Title 10 Sec $130(a)(b)$
(b)(3)(A)(i)\&Title 10 Sec 130 (a)(b)

[^0]| 4. THIE BECTICN FGR GOWEANHIEMTUSE ONLY |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| 日. (XONE) | \{1) Extaing documami suppdaniented by thís NOR <br>  <br>  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
| b. ACTHITY ANTHORIZED TO APPAOVE CHANGE FOA GOVERNMENT |  |  |  |  |
| d. TITLE |  | 9. SICNATUFE |  | f. DATE SAGRED वYMMMDD |
| T6. B. ALTIVITY ACCCOMPLIEHING REVISICN |  | D. REVISHON COMPIFTED \{5, gnatuna $^{\text {a }}$ |  | a. DATE SITMED (अYMHOD |



| Till of Docurpent <br>  | WOR Mo. <br> 3 |
| :---: | :---: |
|  | Daciman Ma. H377786 |



## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 139,375.23$ from $\$ 1,666,362,384.55$ to $\$ 1,666,501,159 . / 8$.

## SUBCLIN 0017AA:

LY: 2102040 SL 5L68 P172419E555L 255Y 4M0J730000 S01021 4M01730000/04MJLE/4M5 was increased by $\$ 139,375.23$ from $\$ 263,836,837.74$ to $\$ 263,976,212.97$

Target Cost, Target Fee, and Total for the above increase of $\$ 139,375.23$ is distributed as follows and includes an increase in target cost of of cost and $\$$ facilities capital cost of money) and an increase in target incentive fee of hich is $\quad$ f target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | :---: |
| Target Fee |  |
| Total | $\$ 139,375.23$ |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:


## * These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00228 showing a summary of funding by ACRN through Modification P00230:

ACRN FUNDING

$$
\begin{array}{lr}
\mathrm{AA} & 440,100.00 \\
\mathrm{AB} & 2,2,98,235.00
\end{array}
$$

| AC | 17,832,987.00 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| AD | 0.00 |  |  |  |  |
| AE | 7,500,000.00 |  |  |  |  |
| AF | 3,300,000.00 |  |  |  |  |
| AG | 17,192,400.00 |  |  |  |  |
| AH | 700,000.00 |  |  |  |  |
| AJ | 200,000.00 |  |  |  |  |
| AK | 85,000.00 |  |  |  |  |
| AL | 45,000.00 |  |  |  |  |
| AM | 17,045,000.00 |  |  |  |  |
| AN | 5,800.00 |  |  |  |  |
| AP | 20,779,000.00 |  |  |  |  |
| AQ | 105,000.00 |  |  |  |  |
| AR | 35,000.00 |  |  |  |  |
| AS | 0.00 |  |  |  |  |
| AT | 6,984,678.52 |  |  |  |  |
| AU | 7,970,000.00 |  |  |  |  |
| AV | 0.00 |  |  |  |  |
| AW | 100,000.00 |  |  |  |  |
| AX | 3,396,000.00 |  |  |  |  |
| AY | 550,000.00 |  |  |  |  |
| AZ | 19,412,000.00 |  |  |  |  |
| BA | 24,527,878.00 |  |  |  |  |
| BB | -146,000.00 |  |  |  |  |
| BC | 72,000.00 |  |  |  |  |
| BD | 85,000.00 |  |  |  |  |
| BE | 100,000.00 |  |  |  |  |
| BF | 100,000.00 |  |  |  |  |
| BG | 1,975,321.00 |  |  |  |  |
| BH | 38,018,908.00 |  |  |  |  |
| BJ | 7,898,834.79 |  |  |  |  |
| BK | 260,000.00 |  |  |  |  |
| BL | 0.00 |  |  |  |  |
| BM | 125,000.00 |  |  |  |  |
| BN | 103,000.00 |  | * | * | \% |
| BP | 10,199,288.50 |  |  |  |  |
| BU | 350,000.00 | $\cdots$ |  | : | $\checkmark$ |
| BV | 9,000.00 |  |  |  |  |
| BW | 84,896,852.00 |  |  |  |  |
| BX | 1,146,000.00 |  |  |  |  |
| BY | 3,880,000.00 |  |  |  |  |
| BZ | 190,000.00 |  |  |  |  |
| KL | 118,250.00 |  |  |  |  |
| KM | 192,793,000.00 |  |  |  |  |
| KN | 0.00 |  |  |  |  |
| KQ | 92,811.00 |  |  |  |  |
| KR | 0.00 |  |  |  |  |
| KS | 0.00 |  |  |  |  |
| KT | 386,377,998.00 |  |  |  |  |
| KU | 2,203,183.00 |  |  |  |  |


| KV | $65,000.00$ |
| :--- | ---: |
| KW | $20,000.00$ |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 263,976,212.97$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 8,573.00$ |
| MD | $\$ 0.00$ |
| ME | $\$ 213,390.00$ |
| MF |  |
| MG | $\$ 6,262,095.00$ |
| MH |  |
|  |  |

3. The following is an update to Modification P00228 showing a summary of funding by CLIN by ACRN through Modification P00230:

| CLIN | ACRN |  | FUNDING AMT |
| :--- | :--- | ---: | ---: |
| CLIN 0001 | AA | $440,100.00$ |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  |  |
|  |  |  |  |
| CLIN 0003 | AB | $2,298,235.00$ |  |
| CLIN 0003 | AC | $17,832,987.00$ |  |

$$
002183
$$

| CLIN 0003 | AD | 0.00 |
| :--- | :--- | ---: |
| CLIN 0003 | AE | $7,500,000.00$ |
| CLIN 0003 | AF | $3,300,000.00$ |
| CLIN 0003 | AG | $17,192,400.00$ |
| CLIN 0003 | AH | $700,000.00$ |
| CLIN 0003 | AM | $17,045,000.00$ |
| CLIN 0003 | AN | $5,800.00$ |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |
| CLIN 0003 | AW | $100,000.00$ |
| CLIN 0003 | AY | $550,000.00$ |


| CLIN 0005 | BA | $24,527,878.00$ |
| :--- | :--- | ---: |
| CLIN 0005 | BB | $146,000.00$ |
| CLIN 0005 | BC | $72,000.00$ |
| CLIN 0005 | BD | $85,000.00$ |
| CLIN 0005 | BE | $100,000.00$ |
| CLIN 0005 | BF | $100,000.00$ |
| CLIN 0005 | BG | $1,975,321.00$ |
| CLIN 0005 | BH | $38,018,908.00$ |
| CLIN 0005 | BL | 0.00 |
| CLIN 0005 | BZ | 0.00 |

$10,199,288.50$

$$
10,199,288.50
$$

| CLIN 0009AA | AQ | $45,106.00$ |
| :--- | :--- | ---: |
| CLIN 0009AA | AV | 0.00 |
| CLIN 0009AA | BK | $256,545.00$ |
| CLIN 0009AA | BM | $125,000.00$ |
| CLIN 0009AA | BN | $21,315.00$ |

$200,000.00$
CLIN 0009AB
AJ
85,000.00
45,000.00
59,894.00
35,000.00
CLIN 0009AB
AQ

CLIN 0009AB
AR
3,455.00
81,685.00
350,000.00
9,000.00
869,034.00

| CLIN 0013 | AU | $7,970,000.00$ |
| :--- | :--- | ---: |
| CLIN 0013 | AX | $3,396,000.00$ |
| CLIN 0013 | AY | 0.00 |
| CLIN 0013 | AZ | $19,412,000.00$ |
| CLIN 0013 | BJ | $7,898,834.79$ |

## CLIN 0017 <br> \section*{CLIN 0017}

BW
0.00
0.00

| $38,676,834.79$ |
| :---: |

KM


| CLIN 0017AA | BY |
| :--- | :--- |
| CLIN 0017AA | BX |
| CLIN 0017AA | BW |
| CLIN 0017AA | BZ |
| CLIN 0017AA | KM |
| CLIN 0017AA | KN |
| CLIN 0017AA | KQ |
| CLIN 0017AA | KS |
| CLIN 0017AA | KT |
| CLIN 0017AA | KU |
| CLIN 0017AA | KY |
| CLIN 0017AA | LC |
| CLIN 0017AA | LD |
| CLIN 0017AA | LE |
| CLIN 0017AA | LH |
| CLIN 0017AA | LJ |
| CLIN 0017AA | LK |
| CLIN 0017AA | LQ |
| CLIN 0017AA | LS |
| CLIN 0017AA | LT |
| CLIN 0017AA | LU |
| CLIN 0017AA | LV |
| CLIN 0017AA | LW |
| CLIN 0017AA | LX |
| CLIN 0017AA | LY |
| CLIN 0017AA | MB |
| CLIN 0017AA | MC |
| CLIN 0017AA | MD |
| CLIN 0017AA | ME |
| CLIN 0017AA | MF |
| CLIN 0017AA | MH |


| CLIN 0017AB | KL | 118,250.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 118,250.00 |
| CLIN 0017AC | BZ | 190,000.00 |  |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AB | KV | 0.00 |  |
| CLIN 0021 AB | LB | 0.00 |  |
| CLIN 0021 AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297.500.00 |


| CLIN 0024 | LG | 62,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

1. SECTION F - DELIVERIES OR PERFORMANCE, paragraph F-5, Milestone Events and Performance Period, is revised as follows:

| MILESTONE EVENT | TIME PERIOD |
| :---: | :---: |
| CLIN 0017 |  |
| Orbit SRR | First Quarter FY07 |
| Orbit SFRR | First Quarter FY07 |
| Orbit SFR | Second Quarter FY07 |
| Platform PDRR | Second Quarter FY07 |
| FCR PDRR/CDRR | Third Quarter FY07 |
| SuR PDRR | First Quarter FY08 |
| Processing Station \& CP PDRR | First Quarter FY08 |
| Platform CDRR | Second Quarter FY08 |
| Orbit PDR | Second Quarter FY08 |
| SuR CDRR | Fourth Quarter FY08 |
| Processing Station \& CP CDRR | Fourth Quarter FY08 |
| Orbit CDR | Second Quarter FY09 |
| System Capability Review \#1 | First Quarter FY11 |
| Fire Control System FVT2 TRR | First Quarter FY11 |
| SuR System FVT2 TRR | First Quarter FY11 |
| Production Readiness Review | First Quarter FY11 |
| Orbit \#1 Developmental Test \#1 Complete (Primary Missions) | Third Quarter FY11 |
| System Capability Review \#2 | Third Quarter FYI1 |
| DT-1 Test Report | Third Quarter FY11 |
| Orbit \#1 Developmental Test \#2 Complete (Secondary Missions) | Fourth Quarter FY11 |
| DT-2 Test Report | First Quarter FY12 |


| Limited User Test (LUT) TRR | First Quarter FY12 |
| :--- | :--- |
| LUT Completion | First Quarter FY12 |
| System Capability Review \#3 | Second Quarter FY12 |
| Logistics Demo \#1 | Fourth Quarter FY12 |
| Orbit \#1 DD 250 | Fourth Quarter FY12 |
| Logistics Demo \#2 | Fourth Quarter FY12 |
| Orbit \#2 DD250 | Fourth Quarter FY13 |

## 2. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 26,878,125.84$ from $\$ 1,666,501,759.78$ to $\$ 1,693,379,885.62$.

CLIN 0013:
BU: 2152040 5Q 5Q17 P172419E55 255Y ER5D730100 S01021 ER5D730100/54KJLE/4K0000 was decreased by $\$ 2,161.45$ from $\$ 7,898,834.79$ to $\$ 7,896,673.34$

SUBCLIN 0017AA:
LT: 2102040 5L 5L68 P172419E555L 255Y 4M0J730000 S01021 4M0J730000/04MJLE/4M5 was increased by $\$ 159,720.29$ from $\$ 263,976,212.97$ to $\$ 264,135,933.26$

MF: 2112040 SL 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 26,720,567.00$ from $\$ 194,771,952.00$ to $\$ 221,492,519.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 26,880,287.29$ is distributed as follows and includes an increase in target cost of ___ of cost and facilities capital cost of money) and a decrease in target fee of

| Target Cost |  |
| :--- | :--- |
| Target Fee |  |
| Total | $\$ 26,880,287.29$ |
|  |  |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c ., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause

THIS
PRIOR
\$1,576,087,940

MODIFICATION
$\$$
0
\$ 1,576,087,940 TOTAL*

CUMULATIVE
for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

3. The following is an update to Modification P00230 showing a summary of funding by ACRN through Modification P00231:

## ACRN FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |
| AD | 0.00 |

$\mathrm{AE} \quad 7,500,000.00$
AF
AG
3,300,000.00
17,192,400.00
AH 700,000.00
AJ 200,000.00
AK $\quad 85,000.00$
AL 45,000.00
AM $\quad 17,045,000.00$
5,800.00
20,779,000.00
105,000.00
35,000.00
AR
0.00

AT
6,984,678.52
7,970,000.00
$\begin{array}{lr}\text { AV } & 0.00 \\ \text { AW } & 100,000.00\end{array}$
AX $\quad 3,396,000.00$
AY
AZ
$550,000.00$
19,412,000.00
24,527,878.00
$146,000.00$
72,000.00
85,000.00
$100,000.00$
$100,000.00$
1,975,321.00
38,018,908.00
BJ $\quad \mathbf{7 , 8 9 6 , 6 7 3 . 3 4}$
BK 260,000.00
BL 0.00

| BM | 125,000.00 |
| :---: | :---: |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |
| KW | 20,000.00 |
| KX | 60,000.00 |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |
| LG | 62,000.00 |
| LH | 400,000.00 |
| LJ | 7,476.00 |
| LK | \$281,575,897.00 |
| LL | \$173,798.00 |
| LM | \$1,410,376.00 |
| LN | \$630,061.00 |
| LP | \$83,200.00 |
| LQ | \$235,566.00 |
| LR | \$125,000.00 |
| LS | \$6,069,616.00 |
| LT | \$530,377.00 |
| LU | \$9,100,000.00 |
| LV | \$1,957,265.00 |
| LW | \$255,567.00 |
| LX | \$68,000.00 |
| LY | \$264,135,933.26 |
| LZ | \$1,751,384.00 |
| MA | \$2,982,442.00 |
| MB | \$375,000.00 |
| MC | \$2,283,481.00 |
| MD | \$8,573.00 |


| ME | $\$ 0.00$ |
| :--- | ---: |
| MF | $\mathbf{\$ 2 2 1 , 4 9 2 , 5 1 9 . 0 0}$ |
| MG | $\$ 6,262,095.00$ |
| MH | $\$ 213,390.00$ |

4. The following is an update to Modification P00230 showing a summary of funding by CLIN by ACRN through Modification P00231:

| CLIN | ACRN | FUNDING AMT CLIN TOTAL |  |
| :--- | :--- | ---: | :--- |
| CLIN 0001 | AA |  |  |
| CLIN 0001 | AD | $440,100.00$ |  |
|  |  | 0.00 |  |
|  |  |  | $440,100.00$ |


| CLIN 0003 | AB | $2,298,235.00$ |
| :--- | :--- | ---: |
| CLIN 0003 | AC | $17,832,987.00$ |
| CLIN 0003 | AD | 0.00 |
| CLIN 0003 | AE | $7,500,000.00$ |
| CLIN 0003 | AF | $3,300,000.00$ |
| CLIN 0003 | AG | $17,192,400.00$ |
| CLIN 0003 | AH | $700,000.00$ |
| CLIN 0003 | AM | $17,045,000.00$ |
| CLIN 0003 | AN | $5,800.00$ |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |
| CLIN 0003 | AW | $100,000.00$ |
| CLIN 0003 | AY | $550,000.00$ |

```
24,527,878.00
    146,000.00
        72,000.00
        85,000.00
        100,000.00
        100,000.00
        1,975,321.00
38,018,908.00
0 . 0 0
    0.00
```

CLIN 0005 BL
CLIN 0005 BZ
$10,199,288.50$
$10,199,288.50$

CLIN 0009AA CLIN 0009AA CLIN 0009AA

BK
BM
BN

CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB CLIN 0009AB

CLIN 0013
CLIN 0013
CLIN 0013
CLIN 0013
CLIN 0013

CLIN 0017
CLIN 0017

CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
CLIN 0017AA
BW
KM
AU
AX
AY
AZ
BJ
AJ
AK
AL
AQ
AR
BK
BN
BU
BV
$256,545.00$
$125,000.00$
$21,315.00$

200,000.00
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00
9,000.00
$7,970,000.00$
$3,396,000.00$
0.00
$19,412,000.00$
$7,896,673.34$
$869,034.00$

38,674,673.34
447,966.00

8,

2

0.00 $\qquad$

```
3,880,000.00
1,146,000.00
84,896,852.00
0.00
192,793,000.00 0.00
66,151.00
0.00
386,204,200.00
2,203,183.00
0.00
200,000.00
7,943,648.00
0.00
400,000.00
7,476.00
281,575,897.00
235,566.00
6,069,616.00
530,377.00
\(\$ 9,100,000.00\)
```



## 002195

| CLIN 0021 AC | $\begin{aligned} & \text { KZ } \\ & \text { LA } \end{aligned}$ | 0.00 |  |
| :---: | :---: | :---: | :---: |
|  |  | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)

## 002196



## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 40,000,000.00$ from $\$ 1,693,379,885.62$ to $\$ 1,733,379,885.62$.

SUBCLIN 0017AA:
MF: 2112040 5L 5L68 P172419E555L 255Y 4M1J730000 S01021 4M1J730000/14MJLE/4M5 was increased by $\$ 40,000,000.00$ from $\$ 221,492,519.00$ to $\$ 261,492,519.00$

Target Cost, Target Fee, and Total for the above increase of $\$ 40,000,000$ is distributed as follows and includes an increase in target cost of $\quad$ facilities capital cost of money) and an increase in target fee of


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

2. The following is an update to Modification P00231 showing a summary of funding by ACRN through Modification P00232:

## ACRN FUNDING

```
AA
    440,100.00
AB
2,298,235.00
```

| AC | 17,832,987.00 |
| :---: | :---: |
| AD | 0.00 |
| AE | 7,500,000.00 |
| AF | 3,300,000.00 |
| AG | 17,192,400.00 |
| AH | 700,000.00 |
| AJ | 200,000.00 |
| AK | 85,000.00 |
| AL | 45,000.00 |
| AM | 17,045,000.00 |
| AN | 5,800.00 |
| AP | 20,779,000.00 |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018;908.00 |
| BJ | 7,896,673.34 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |

## 002199

| KV | $65,000.00$ |
| :--- | ---: |
| KW | $20,000.00$ |
| KX | $60,000.00$ |
| KY | $25,000.00$ |
| KZ | $25,000.00$ |
| LA | $13,508.00$ |
| LB | $12,500.00$ |
| LC | $200,000.00$ |
| LD | $7,943,648.00$ |
| LE | $1,173,850.00$ |
| LF | $10,000.00$ |
| LG | $62,000.00$ |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 264,135,933.26$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 8,573.00$ |
| MD | $\$ 0.00$ |
| ME | $\$ 261,492,519.00$ |
| MF | $\$ 6,262,095.00$ |
| MG |  |
| MH |  |
|  | $\$ 90.00$ |

3. The following is an update to Modification P00231 showing a summary of funding by CLIN by ACRN through Modification P00232:

| CLIN | ACRN | FUNDING AMT |
| :--- | :--- | ---: |
|  |  |  |
| CLIN 0001 | AA | $440,100.00$ |
| CLIN 0001 | AD | 0.00 |
|  |  |  |
|  |  |  |
| CLIN 0003 | AB | $2,298,235.00$ |
| CLIN 0003 | AC | $17,832,987.00$ |


| CLIN 0003 | AD | 0.00 |
| :--- | :--- | ---: |
| CLIN 0003 | AE | $7,500,000.00$ |
| CLIN 0003 | AF | $3,300,000.00$ |
| CLIN 0003 | AG | $17,192,400.00$ |
| CLIN 0003 | AH | $700,000.00$ |
| CLN 0003 | AM | $17,045,000.00$ |
| CLIN 0003 | AN | $5,800.00$ |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |
| CLIN 0003 | AW | $100,000.00$ |
| CLIN 0003 | AY | $550,000.00$ |

$$
94,288,100.52
$$

```
24,527,878.00
    146,000.00
        72,000.00
        85,000.00
        100,000.00
        100,000.00
    1,975,321.00
38,018,908.00
                0.00
        0 . 0 0
```

    \(10,199,288.50\)
    CLIN 0009AA

| CLIN 0009AB | AJ | $200,000.00$ |
| :--- | :--- | ---: |
| CLIN 0009AB | AK | $85,000.00$ |
| CLIN 0009AB | AL | $45,000.00$ |
| CLIN 0009AB | AQ | $59,894.00$ |
| CLIN 0009AB | AR | $35,000.00$ |
| CLIN 0009AB | BK | $3,455.00$ |
| CLIN 0009AB | BN | $81,685.00$ |
| CLIN 0009AB | BU | $350,000.00$ |
| CLIN 0009AB | BV | $9,000.00$ |
|  |  |  |


| CLIN 0013 | AU |
| :---: | :---: |
| CLIN 0013 | AX |
| CLIN 0013 | AY |
| CLIN 0013 | AZ |
| CLIN 0013 | BJ |
| CLIN 0017 | BW |
| CLIN 0017 | KM |
| CLIN 0017AA | BY |
| CLIN 0017AA | BX |
| CLIN 0017AA | BW |
| CLIN 0017AA | BZ |
| CLIN 0017AA | KM |
| CLIN 0017AA | KN |
| CLIN 0017AA | KQ |
| CLIN 0017AA | KS |
| CLIN 0017AA | KT |
| CLIN 0017AA | KU |
| CLIN 0017AA | KY |
| CLIN 0017AA | LC |
| CLIN 0017AA | LD |
| CLN 0017AA | LE |
| CLIN 0017AA | LH |
| CLIN 0017AA | LJ |
| CLIN 0017AA | LK |
| CLIN 0017AA | LQ |
| CLIN 0017AA | LS |
| CLIN 0017AA | LT |
| CLIN 0017AA | LU |
| CLIN 0017AA | LV |
| CLIN 0017AA | LW |
| CLIN 0017AA | LX |
| CLIN 0017AA | LY |
| CLIN 0017AA | MB |
| CLIN 0017AA | MC |
| CLIN 0017AA | MD |
| CLIN 0017AA | ME |
| CLIN 0017AA | MF |
| CLIN 0017AA | MH |

7,970,000.00
3,396,000.00
0.00
19,412,000.00
7,896,673.34
38,674,673.34
0.00 ..... 0.00
$\qquad$
$3,880,000.00$
1,146,000.00
84,896,852.00 0.00

192,793,000.00 0.00

66,151.00 0.00

386,204,200.00 2,203,183.00 0.00

200,000.00
7,943,648.00 0.00

400,000.00
7,476.00
281,575,897.00
235,566.00
6,069,616.00
530,377.00
$\$ 9,100,000.00$
\$1,957,265.00
$\$ 255,567.00$
\$68,000.00
$\$ 264,135,933.26$
$\$ 375,000.00$
$\$ 2,283,481.00$
\$8,573.00
$\$ 0.00$ $\qquad$
\$261,492,519.00
$\$ 213,390.00$ $\qquad$ $1,508,041,694.26$

## 002202

| CLIN 0017AB | KL | 118,250.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 118,250.00 |
| CLIN 0017AC | BZ | 190,000.00 |  |
|  |  |  | 190,000.00 |
| CLIN 0017AD | KN | 0.00 |  |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021 AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021 AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
|  |  | 02 |  |


| CLIN 0024 | LG | 62,000.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

(End of Summary of Changes)

8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, Sate and Zip Code) PAYTHEON COMPANY
350 LONE 5 T.
ANDOVER MA OTO1O-400
CODE 05716 TEACILITYCODE

|  | SA. AMENDMENT OF SOLICITATIONNO. |
| :--- | :--- |
|  | SB. DATED (SEE ITEM II) |
| $\times$ | OASMOD. OFCONTRACTIORDER NO. |
| $\times$ | 10B. DATED (SEE ITEM 13) <br> 30-Jan-1998 |

## II. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

The above numbered solicitation is amended as see forth in Item 14. The hour and dace specified for receipt ofolisr
OEE must ackacwiedge reoalpt of this amendment prior to the hour and dime specified in the solicitation or as amended by one of the following methods: (a) By completing frets 8 and IS, and returning copies of the amendurat; (b) By acknowledging receipt of this amendment on each copy of the of er submitted; or (c) By septate letter or lelegramwhich tneludes a reference to the solicitation and amendment numbers. FAIL URE OF YOUR ACKNOWLEDGMENTIO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN
 provided each icel egramor letter mokes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
12. ACOOUNTING AND APPROPRIATION DATA (If required) See Schedule
13. THIS IT EM APPLIES ONLY TO MODIFICATIONS OF CONTRACTSORDERS IT MODIFIES THE CONTRACTKODER NO. AS DESCRIBED IN ITEM 14.
A. THIS CHANGE ORDER IS ISUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM I4 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM IDA.
B. THE ABOVE NUMBERED CONTRACTMORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM (4, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
X C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 52.232-22, "Lintation of Funds" and Mutual Agreamemt
D. OTHER (Specify type of modification and authority)
E. IMPORTANT: Contractor $\square$ is not, $X$ is required to sign this document and ret tran 1 copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Modification Control Number
To increase and fund SubCLNourfAA in the amount of s914,571 as settlement of the proposal submitted by the contractor in reanonento a Government request to replace (b) (3)(A) hardw are in the two (2) Orbits fobedelily the contractor w Il provide hardy are that is required to replace the harcww are that is located in the HEVS Product Office (NOO) SLS.

Except as provided herein. all terms and conditions of he document referenced in hem9A or 10A. as hertobre changed, retinas unchanged and in fill force and effect.


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1. SECTION A - SOLIICITATION/CONTRACT FORM

## 836

The total cost of this contract was increased by $\$ 914,571.00$ from $\$ 1,813,878,387.00$ to \$1,814,790,958.00.

750

## 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

## SUBCLIN 0017AA


 in facilities capital cost of money, and an increase in target fee of facilities capital cost of money.

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:


FAR 52.216-10, NCENTIVE, paragraph (e)(1), is stated as follows:
(e) Fee Payable.
(1) The fee payable under this contract shall be the target fee increased by nts for every dollar that the total allowable cost is less than the target cost or decreased by ents for every dollar that the total allowable cost exceeds the target cost. In no event shall the fee be greater than Jercent or less thar ercent of the target cost.

## B-18. TARGET COST. TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA - (Two SDD JLENS Systems)


## 3. SECTION G-CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 914,571.00$ from $\$ 1,733,379,885.62$ to $\$ 1,734,294,456.62$.

SUBCLIN 0017AA:
MJ: 2112040 5L 5L68 P172419E555L 255Y 4M1J741000 S01021 4M1J741000/14MJLE/4M5 was increased by $\$ 858,495.00$ from $\$ 0.00$ to $\$ 858,495.00$

The contract ACRN MJ has been added.
MK: 2112040 5L 5L68 P172419E555L 255Y 4M1J741100 S01021 4M1J741100/14MJLE/4M5 was increased by $\$ 56,076.00$ from $\$ 0.00$ to $\$ 56,076.00$

The contract ACRN MK has been added.
Target Cost, Target Fee, and Total for the above increase of $\$ 914,571$ is distributed as follows and includes an increase in target cost of cost and of facilities capital cost of money) and an increase in target incentive fee of which i of target cost less facilities capital cost of money.


IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:


[^1]
## SubCLIN 17AH)

## 4. SECTION H - SPECLAL CONTRACT REQUIREMENTS is changed as follows:

## Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLN 0017 . SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs a. and b., are revised as follows:

## a. General.

SubCLIN 0017 AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of $\$ 1,577,002,511$ includes a target cost of (which includes _ f cost and $\$ 12 \longrightarrow$ facilities capital cost of money) and a target incentive fee of 0 which is target cost less facilities capital cost money.
b. Cost Incentive.
(1) The target fee payable under SubCLIN 0017AA
( an amount equal to the target cost less facilities capital cost of money

(2) The maximum fee payable under SubCLIN O017AA is farget cost less facilities capital cost of money an amount equal to
(3) The minimum fee payable under SubCLIN 0017AA $\longrightarrow f$ the target cost less facilities capital cost of money an amount equal to
(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio Fovernment Contractor for actual costs less than the target cost, and a ratio o Government / ractor for actual costs greater than the target cost range applied according to Paragraph $\mathrm{H}-19(\mathrm{c})(1)$.
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.


## 002208

(2) An additional performance incentive fee pool of (maximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:
(a) (maximum) earned based on successful conduct of technical performance defined by SCR-1.
(b) maximum) earned based on successful conduct of technical performance defined by SCR-2.
(c) maximum) earned based on successful conduct of technical performance defined by SCR-3.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section J attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is earned.
(3) For Earned Value and cost reporting purposes, the target cost value of will be used.
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.
5. The following is an update to Modification P00231 showing a summary of funding by ACRN through Modification P00232:

## ACRE FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |
| AD | 0.00 |
| AE | $7,500,000.00$ |
| AF | $3,300,000.00$ |
| AG | $17,192,400.00$ |
| AH | $700,000.00$ |
| DJ | $200,000.00$ |
| AK | $85,000.00$ |
| AL | $45,000.00$ |
| AM | $17,045,000.00$ |
| AN | $5,800.00$ |

## 002209

| AP | 20,779,000.00 |
| :---: | :---: |
| AQ | 105,000.00 |
| AR | 35,000.00 |
| AS | 0.00 |
| AT | 6,984,678.52 |
| AU | 7,970,000.00 |
| AV | 0.00 |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,896,673.34 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |
| KW | 20,000.00 |
| KX | 60,000.00 |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |

## 002210

| LG | $62,000.00$ |
| :--- | ---: |
| LH | $400,000.00$ |
| LJ | $7,476.00$ |
| LK | $\$ 281,575,897.00$ |
| LL | $\$ 173,798.00$ |
| LM | $\$ 1,410,376.00$ |
| LN | $\$ 630,061.00$ |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 264,135,933.26$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 0.00$ |
| MF | $\$ 261,492,519.00$ |
| MG | $\$ 6,262,095.00$ |
| MH | $\$ 213,390.00$ |
| MJ | $\$ 858,495.00$ |
| MK | $\$ 56,076.00$ |
|  |  |

6. The following is an update to Modification P00231 showing a summary of funding by CLIN by ACRN through Modification P00232:

| CLIN | ACRN | FUNDING AMT |  |
| :--- | :--- | ---: | :--- |
| CLIN TOTAL |  |  |  |
| CLIN 0001 | AA | $440,100.00$ |  |
| CLIN 0001 | AD | 0.00 |  |
|  |  |  | $440,100.00$ |


| CLIN 0003 | AB | $2,298,235.00$ |
| :--- | :--- | ---: |
| CLIN 0003 | AC | $17,832,987.00$ |
| CLIN 0003 | AD | 0.00 |
| CLIN 0003 | AE | $7,500,000.00$ |
| CLIN 0003 | AF | $3,300,000.00$ |
| CLN 0003 | AG | $17,192,400.00$ |
| CLIN 0003 | AH | $700,000.00$ |
| CLIN 0003 | AM | $17,045,000.00$ |
| CLIN 0003 | AN | $5,800.00$ |
| CLIN 0003 | AP | $20,779,000.00$ |
| CLIN 0003 | AS | 0.00 |
| CLIN 0003 | AT | $6,984,678.52$ |

CLIN 0003
CLIN 0003
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005

CLIN 0007AA

CLIN 0009AA
CLIN 0009AA AV CLIN 0009AA CLIN 0009AA CLIN 0009AA

CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB

CLIN 0013
CLIN 0013
CLIN 0013
CLIN 0013
CLIN 0013
AU
AX
AY
AZ
BJ

CLIN 0017
CLIN 0017

BP

AQ

BK

AJ
AK
AL
AQ
AR
BK
BN
BU
BV
BA
BB

## BC

## BD

BE
BF

## BG

## BH

BL

## BZ

100,000.00
550,000.00
$24,527,878.00$
$146,000.00$
$72,000.00$
$85,000.00$
$100,000.00$
$100,000.00$
$1,975,321.00$
$38,018,908.00$
0.00
0.00

94,288,100.52

24,527,878.00
$146,000.00$
72,000.00
85,000.00
100,000.00
$100,000.00$
1,975,321.00
38,018,908.00
0.00 0.00

65,025,107.00
$10,199,288.50$
$10,199,288.50$

45,106.00
0.00

256,545.00
125,000.00
21,315.00 $\qquad$

\[

\]

7,970,000.00
$3,396,000.00$
0.00

19,412,000.00
7,896,673.34


002213

|  | KN | 0.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0017AD | KS | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0017AE | LL | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021 AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
|  |  | $0221$ |  |


| CLIN 0025 | LM | 1,080,404.00 |  |
| :---: | :---: | :---: | :---: |
| CLIN 0025 | MA | 0.00 |  |
|  |  |  | 2,254,254.00 |
| CLIN 0026 | LN | 630,061.00 |  |
|  |  |  | 630,061.00 |
| CLIN 0027 | LZ | 1,751,384.00 |  |
|  |  |  | 1,751,384.00 |
| CLIN 0028 | LM | 329,972.00 |  |
| CLIN 0028 | MA | 2,982,442.00 |  |
| CLIN 0028 | MG | 6,262,095.00 |  |
|  |  |  | 9,574,509.00 |

[^2] (i) \&Title
(End of Summary of Changes)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by $\$ 116,044.00$ from $\$ 1,814,750,958.00$ to $\$ 1,814,867,002.00$.

## 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

## SUBCLIN 0017AA

The target cost has increased by
The target profit/fee has increased by $\longrightarrow$. The total cost of this line item has increased by

(b) (4)
(b) ${ }^{(4)}(b)$
bl
(b) $(4)$
(b)(4) facilities capital cost of money, and an increase in target fee on which is f target cost less facilities capital cost of money.

## B-17. NCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AA/CLIN 0018 are set forth below:

Target Cost
Target Fee
 fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:
(e) Fee Payable.
(1) The fee payable under this contract shall be the target fee increased by ants for every dollar that the total allowable cost is less than the target cost or decreased $b$. Ins for every dollar that the total allowable cost exceeds the target cost. In no event shall the fee be greater thar the nt or less the target cost.

B-18. TARGET COST, TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA - (Two SDD JLENS Systems)
a. Target cost:
b. Target fee:


## 3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation
Summary for the Payment Office
As a result of this modification, the total funded amount for this document was increased by $\$ 116,044.00$ from $\$ 1,734,294,456.62$ to $\$ 1,734,410,500.62$.

## SUBCLIN 0017AA:

ML: 21 I 2040 5L 5L68 P172419E555L 255Y 4M1J741200 S01021 4M1J741200/14MJLE/4M5 was increased by $\$ 116,044.00$ from $\$ 0.00$ to $\$ 116,044.00$

The contract ACRN ML has been added.
Target Cost, Target Fee, and Total for the above increase of $\$ 116,044$ is distributed as follows and includes an increase in target cost of facilities capital cost of money) and an increase in target incentive fee of target cost less facilities capital cost of money.

| Target Cost |  |
| :--- | ---: |
| Target Fee |  |
| Total | $\$ 116,044$ |
|  |  |

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA :
(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)

4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is changed as follows:
a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph $\mathrm{H}-19$ (b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price amount of $\$ 1,577,118,555$ includes a target cost of $\xrightarrow{\text { which includes }}$ of cost and acilities capital cost of money) and a target incentive fee which is farget cost less facilities capital cost of money.
b. Cost Incentive.
(1) The target fee payable under SubCLIN 0017AA is the target cost less facilities capital cost of money
(2) The maximum fee payable under SubCLIN 0017AA i the target cost less facilities capital cost of
money anount equal t
(3) The minimum fee payable under SubCLIN O017AA the target cost less facilities capital cost of money $\rightarrow$ an amount equal $t$
(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio Government Contractor for actual costs less than the target cost, and a ratio o Government/
(5) Nothing stated in this clause shall take precedence over the clause 52.216-10-Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.
(1) A maximum 'flat zone" will be established at the target cost value of ith the conduct of milestones below. The "flat zone" over which the contractor will earn target ree is for eligible costs from once the program milestones set forth below are conducted.
(a) of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007 from
(b) Dof the maximum benefit of the "flat zone", eamed by the conduct of SDD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, from
(2) An additional performance incentive fee pool of naximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:

[^3](b) (maximum) earned based on successful conduct of technical performance defined by SCR-2.
(c) Maximum) earned based on successful conduct of technical performance defined by SCR-3.
(d) maximum) earned based on successful conduct of technical performance defined by LUT.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section J attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is earned.
(3) For Earned Value and cost reporting purposes, the target cost value of $\$ 1,447,892,193$ will be used.
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.
5. The following is an update to Modification P00233 showing a summary of funding by ACRN through Modification P00234:

## ACRN FUNDING

| AA | $440,100.00$ |
| :--- | ---: |
| AB | $2,298,235.00$ |
| AC | $17,832,987.00$ |
| AD | 0.00 |
| AE | $7,500,000.00$ |
| AF | $3,300,000.00$ |
| AG | $17,192,400.00$ |
| AH | $700,000.00$ |
| AU | $200,000.00$ |
| AK | $85,000.00$ |
| AL | $45,000.00$ |
| AM | $17,045,000.00$ |
| AN | $5,800.00$ |
| AP | $20,779,000.00$ |
| AQ | $105,000.00$ |
| AR | $35,000.00$ |
| AS | 0.00 |
| AT | $6,984,678.52$ |
| AU | $7,970,000.00$ |


| AV | 0.00 |
| :---: | :---: |
| AW | 100,000.00 |
| AX | 3,396,000.00 |
| AY | 550,000.00 |
| AZ | 19,412,000.00 |
| BA | 24,527,878.00 |
| BB | 146,000.00 |
| BC | 72,000.00 |
| BD | 85,000.00 |
| BE | 100,000.00 |
| BF | 100,000.00 |
| BG | 1,975,321.00 |
| BH | 38,018,908.00 |
| BJ | 7,896,673.34 |
| BK | 260,000.00 |
| BL | 0.00 |
| BM | 125,000.00 |
| BN | 103,000.00 |
| BP | 10,199,288.50 |
| BU | 350,000.00 |
| BV | 9,000.00 |
| BW | 84,896,852.00 |
| BX | 1,146,000.00 |
| BY | 3,880,000.00 |
| BZ | 190,000.00 |
| KL | 118,250.00 |
| KM | 192,793,000.00 |
| KN | 0.00 |
| KQ | 92,811.00 |
| KR | 0.00 |
| KS | 0.00 |
| KT | 386,377,998.00 |
| KU | 2,203,183.00 |
| KV | 65,000.00 |
| KW | 20,000.00 |
| KX | 60,000.00 |
| KY | 25,000.00 |
| KZ | 25,000.00 |
| LA | 13,508.00 |
| LB | 12,500.00 |
| LC | 200,000.00 |
| LD | 7,943,648.00 |
| LE | 1,173,850.00 |
| LF | 10,000.00 |
| LG | 62,000.00 |
| LH | 400,000.00 |
| LJ | 7,476.00 |
| LK | \$281,575,897.00 |
| LL | \$173,798.00 |
| LM | \$1,410,376.00 |

## 002221

| LN | $\$ 630,061.00$ |
| :--- | ---: |
| LP | $\$ 83,200.00$ |
| LQ | $\$ 235,566.00$ |
| LR | $\$ 125,000.00$ |
| LS | $\$ 6,069,616.00$ |
| LT | $\$ 530,377.00$ |
| LU | $\$ 9,100,000.00$ |
| LV | $\$ 1,957,265.00$ |
| LW | $\$ 255,567.00$ |
| LX | $\$ 68,000.00$ |
| LY | $\$ 264,135,933.26$ |
| LZ | $\$ 1,751,384.00$ |
| MA | $\$ 2,982,442.00$ |
| MB | $\$ 375,000.00$ |
| MC | $\$ 2,283,481.00$ |
| MD | $\$ 8,573.00$ |
| ME | $\$ 0.00$ |
| MF | $\$ 261,492,519.00$ |
| MG | $\$ 6,262,095.00$ |
| MH | $\$ 213,390.00$ |
| MJ | $\$ 858,495.00$ |
| MK | $\$ 56,076.00$ |
| ML | $\$ 116,044.00$ |

6. The following is an update to Modification P00231 showing a summary of funding by CLIN by ACRN through Modification P00232:

## CLIN

CLIN 0001
CLIN 0001

AB
AC
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003
CLIN 0003

AA
AD
ACRN

A

## FUNDING AMT CLIN TOTAL

$440,100.00$
0.00
$440,100.00$

2,298,235.00
17,832,987.00
0.00

7,500,000.00
3,300,000.00
17,192,400.00 700,000.00
$17,045,000.00$
$5,800.00$
20,779,000.00
0.00

6,984,678.52
$100,000.00$
$550,000.00$

[^4]CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005
CLIN 0005

BA
BB
BC
BD
BE
BF BG BH BL BZ CLIN 0007AA BP

B

$$
\begin{array}{r}
24,527,878.00 \\
146,000.00 \\
72,000.00 \\
85,000.00 \\
100,000.00 \\
100,000.00 \\
1,975,321.00 \\
38,018,908.00 \\
0.00 \\
0.00
\end{array}
$$

$$
65,025,107.00
$$

$10,199,288.50$

$$
10,199,288.50
$$

$$
45,106.00
$$

$\begin{array}{ll}\text { CLIN 0009AA } & \text { AQ } \\ \text { CLIN 0009AA } & \text { AV }\end{array}$
CLIN 0009AA
AV CLIN 0009AA

BK
BM CLIN 0009AA

BN

CLIN 0009AB
CLIN 0009AB
AJ

CLIN 0009AB
AK

CLIN 0009AB
AL

CLIN 0009AB
AQ

CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
CLIN 0009AB
AR
BK
BN
BU
BV

CLIN 0013
AU
CLIN 0013
AX
CLIN 0013
AY
CLIN 0013
AZ
CLIN 0013
BJ

CLIN 0017
BW
CLIN 0017
KM

CLIN 0017AA
BY
BX
BW
0.00

256,545.00
125,000.00
21,315.00

200,000.00
85,000.00
45,000.00
59,894.00
35,000.00
3,455.00
81,685.00
350,000.00
9,000.00 $\qquad$

7,970,000.00
3,396,000.00
0.00

19,412,000.00
7,896,673.34
.0 .00
0.00 $\qquad$
$869,034.00$


3,880,000.00
1,146,000.00
84,896,852.00

## CLIN 0017AA



| CLIN 0017AE | LL | 173,798.00 |  |
| :---: | :---: | :---: | :---: |
|  |  |  | 173,798.00 |
| CLIN 0017AH | KT | 173,798.00 |  |
|  |  |  | 173,798.00 |
| CLIN 0020AA | KN | 0.00 |  |
| CLIN 0020AA | KQ | 26,660.00 |  |
|  |  |  | 26,660.00 |
| CLIN 0021AA | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AB | KV | 0.00 |  |
| CLIN 0021AB | LB | 0.00 |  |
| CLIN 0021AB | KX | 0.00 |  |
| CLIN 0021AB | KY | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0021AC | KZ | 0.00 |  |
| CLIN 0021AC | LA | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0022 | KW | 0.00 |  |
|  |  |  | 0.00 |
| CLIN 0023 | KX | 60,000.00 |  |
| CLIN 0023 | KY | 25,000.00 |  |
| CLIN 0023 | KV | 65,000.00 |  |
| CLIN 0023 | LB | 12,500.00 |  |
| CLIN 0023 | LF | 10,000.00 |  |
| CLIN 0023 | LR | \$125,000.00 |  |
|  |  |  | 297,500.00 |
| CLIN 0024 | LA | 13,508.00 |  |
| CLIN 0024 | LG | 62,000.00 |  |
| CLIN 0024 | KZ | 25,000.00 |  |
| CLIN 0024 | KW | 20,000.00 |  |
| CLIN 0024 | LP | 83,200.00 |  |
|  |  |  | 203,708.00 |
| CLIN 0025 | LE | 1,173,850.00 |  |
| CLIN 0025 | LM | 1,080,404.00 |  |
| CLIN 0025 | MA | 0.00 |  |

## 002225


7. In consideration of the modification agreed to herein as complete equitable adjustment for the proposal submitted via Raytheon letter JLENS-23414-11-054, dated 09 June 2011, the Contractor hereby Sec 130 (a)(b) releases the Government from any and all liability under this contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposal for adjustment.
(End of Summary of Changes)

AMENDMENT OF SOLICITATIONMODIFICATION OF CONTRACT

| 1.CONTRACTID CODE | PAGE OF PAOES |  |
| :---: | :---: | :---: |
| $V$ | 1 | 5 |


9A. AMENDMENT OF SOLICITATIONNO.

RAYTHEON COMPANY
s30LOMEISST.
ANDOVER MA OR1010-400
$\qquad$ IFACILTYCODE

|  | 9A. AMENDMENT OF SOLICITATIONNO. |
| :--- | :--- |
| 9B. DATED (SEE ITEM 1I) |  |
| $\times$ | 10A. MOD. OFCONTRACT/ORDER NO. <br> DASC6-68-COOO1 |
| $\times$IOB. DATED (SEE ITEM 13) <br> 30-JEn-1998 |  |

## 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICIT ATIONS


Ofier must acknowtedge receipt of this arendarint prior to the hour and dexe specified in the solicitaiton or as amended by one of the sollawiag arel hods: (a) By completing fiems 8 and 15 , and secturning $\qquad$ copies of the amendment: (b) By acknowiodging receipt orthis amsadmunt on each copy of the oller subtmitted: or (c) By separate leter or telogram which includes a refertnce to the solicitation and amendment numbers. FAIL URE OF YOUR ACKNOWLEDGMENTTO BE RECEIVED ATTHE PLACE DESIGNATED FOR THE RECEIPTOF OFFERS PRIOR TO THE HOUR AND DATE SPECIFJED MAY RESULTIN REEECION OF YOUR OFFER. Ifby virtuc of this amsadmein you desire to change an ofer slready submitted. such change may be nade by telegramor fetter. provided esch ielegramor letier makes refrence to the solicitation and this ammendrent. and is received prior to the opening hour and date specified.
12. ACCOUNTING AND APPROPRIATION DATA (If required)
13. THISITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTSORDERS. IT MODIFIES THE CONTRACTIORDER NO. AS DESCRIBED IN ITEM 14.
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM I4 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM IOA.
B. THE ABOVE NUMBERED CONTRACT/ORDER ISMODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (uch as changes in paying office, approprimion date. etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(B).
X C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:
FAR 43.103(a)(3), Mitual Agreement
D. OTHER (Specify lype of modification and auhhority)
E. IMPORTANT: Contractor $\square$ is not. $\bar{x}$ is required to sign this document and return 1 copies to the issuing office.
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Comirol Number
(b)(6)

To revise the D0254, Contract Security Classitication Specilication at no additional cost to the Government.



## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

| TITLE | DATE | \# OF PAGES |
| :---: | :---: | :---: |
| ect Security Classification Specification (DD Form 254), 13 (Added per Modification P00235) | 14 Apr 11 | 13 |

JLENS Software Source Code Specifically Negotiated License, 04 Sep 08
License Number JLENS-SWLA-01
(Added per Modification P00166)

## CLIN 0017:

JLENS System Development and Demonstration (SDD) Program Statement of Work (Revised by

30 Nov 06 Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification P00136)

JENS System Development and Demonstration

Contract Data Requirements List (DD Form 1423)
Exhibit A with Distribution List \& Data Item
Nos. B001 through B062
(Replace Data Item Nos. B026 and B027, only
Per Modification P00136)
(Replace Data Item Nos. B048 and B049, only
Per Modification P00143 \& to add statement in
Section A of Modification P00143)
$\begin{array}{ll}\text { (Replace Data Item No. B033 only, per } & \text { Revised 11 Jul 08 . } 1 \\ \text { Modification P00161) } & \end{array}$
Contract Data Requirements List (DD Form 1423)
Exhibit A, Data Item Nos. B001 and B014
(Added per Modification P00187)
Contract Data Requirements List (DD Form 1423)
Exhibit A, Data Item Nos. B002 through B062 (less B014)
(Added per Modification P00187)

Revised 06 Apr 09

01 Dec 06

Revised 05 Apr 07

Revised 20 Mar 09
60
Revised 20 Feb 07

Revised 24 Oct 07

Revised 07 May 09
2
63

Revised 20 Mar 09
*Added statement below to address weekends/Holidays:
24 October 07 (In Mod P00143)
*Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DD Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Government Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for resubmittal will begin on the next business day. Statement added in Mod P00143 on 24 Oct. 2007.

GFE/GFP/GFS List for SDD
Replaced with Rev. B List
**Add items below
For record-keeping purposes
(Per Mod P00143)
Replaced with Revision C List (Per Modification P00183)
Replaced with Revision D List
(Per Modification P00207)
28 Nov $06 \quad 2$

15 Oct 076
Revised 22 Oct 07

09 Mar 09
12
23 Feb 10
11
**Per the DCMA and $\quad$ Raytheon is authorized rent free use on a non-interference use of (b)(4) the equipment listed below for utilization on JLENS Fire Control Radar Prime Contract DASG60-98-C0001 for the period from 19 April 2007 through 30 September 2011.
(b)(3)
(A)

Hereby added in Mod P00148 for tracking purposes:
Originated in Basic Contract:
Government Furnished Equipment - Spiral 1
(Spiral 1 Equipment Transferred to Government
Contract DASG60-00-C-0091, DD Form 1149 (attached)
(b)(6)

Gov't Technical POC:
Ship to address:

(b) (4)
*NOTE: Items 1-1060 transferred to Contract DASG60-00-C-0091 per revised GFE list dated 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98-C-0001 for Spiral 2 per GFE list dated 25 Mar 07.

JLENS Performance Specification, MIS-PRF-55628,
27 Jun 08
136
Revision A
(Added by reference per Modification P00168)
Annex A to the JLENS Performance Specification, MIS-PRF-55628, Revision A
(Added by reference per Modification P00168)
JLENS SDD DD250 Plan 11 Dec 09 ..... 5
(Added per Modification P00207)
Performance Incentive Fee Criteria/Evidence
(Revised per Modification P00227)
Engineering Change Proposal (ECP) MI-N3893,Revision 2, CDRL B039-005b
Engineering Change Proposal (ECP) MI-N3894,CDRL B039-006
Engineering Change Proposal (ECP) MI-N3895,CDRL B039-007
CLINs 0023 and 00024
JLENS Simulation SupportSOW dated 28 January 2008
Simulation Support Tasks
(Added per Mod P00160)
CLIN 0025
JLENS Integrated Fire Control Demonstration Program ..... $14 \operatorname{Sep} 09$
Statement of Work, Revision 5
(Added per Modification P00211)
JLENS Integrated Fire Control Demonstration Program ..... 30 Mar 10
Program and Technical Clarification Description,incorporated herein by reference(Added per Modification P00211)
Contract Data Requirements List (DD Form 1423)16 Oct 07Exhibit B, Data Items Nos. B001 through B004, withData Item Descriptions
(Added per Modification P00165)
Contract Data Requirements List (DD Form 1423),16 Jun 10
CLIN 0028, Exhibit B, Data Item Nos. B001 through B006
(Added per Modification P00211)
CLIN 0027
JLENS System Integration Lab (SIL)Undated6
Equipment List
(Added per Modification P00196)
Revision to System Integration Lab (SIL) 02 Aug 10 ..... 6
Undated15 Nov 1018 Aug 1028 Sep 1028 January $2008 \quad 2$ pages
(b)(3)(A)(i)\&Title10 Sec 130 (a)(b)

Equipment List
(Added per Modification P00217)
(End of Summary of Changes)

002231

## DEPARTMENT OF DEFENSE

## CONTRACT SECURITY CLASSIFICATION SPECIFICATION

(The requirements of the DOO Industrial Security Manual apply to all security aspects of this effort.)


## DD FORM 254 Front


 ] uned XI itrough repoefi.

## 



 cavire worm



Esimated dab of completion of the contract te 30 saplamber 2013.
8et continuallon pages for additional securly gutdance.



(b)(7)(E)
(b)(7)(E)


002236


002237
(b)
(7)
(b)
(b)




## AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

| AMENDMENT/MODIFICATION NO. P00236 | 3 EFFECTIVE DATE $19-\mathrm{Jul}-2011$ | 4 REQUISITION/PURCHASE REQ. NO |  | 5 PROJECT NO (Ifapplicable) |
| :---: | :---: | :---: | :---: | :---: |
| 6. ISSUED BY USASMDC/ARSTRAT SMDC-RDC POBOX 500 HUNTSVUE AL $38807-3801$ | W9113M | 7. ADMINISTERED BY (Ifother than item6) DCMARAYTHEON 50 APPLE HILL DRIVE M/S T2FR2 TEWKSBURYMA 01876 | CODE | E S2205A |
| 8. NAME AND ADDRESS OF CONTRACT OR (No., Street, County, State and Zip Code) RAYTHEON COMPANY 350 LOWEL ST ANDOVER MA 01810-4400 |  |  | 9A. AMENDMENT OF SOLICITATION NO. |  |
|  |  |  | 9B. DATED (SEE ITEM 11) |  |
|  |  |  | 10A. MOD. OF CONTRACT/ORDER NO. DASG60-98-C-0001 |  |
|  |  |  | $\begin{aligned} & \text { 10B. DATED (SEE ITEM 13) } \\ & \text { 30-Jan-1998 } \end{aligned}$ |  |
| CODE 05716 | FACILITY CODE |  |  |  |
| 11 THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICIT ATIONS |  |  |  |  |
| The above numbered solicitation is amended as set forth in Item 14 . The hour and date specifed for receipt ofOfter $\square$ is extended, $\square$ is not excended Ofer must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended by one ofthe fillowing methods: <br> (a) By completing ltems 8 and 15 , and returning $\qquad$ copies ofthe amendment; (b) By acknowledging receipt ofthis amendment on each copy ofthe offer subritted; or (c) By separate letter or telegram which includes a refierence to the solicitation and amendment numbers FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED ATTHE PLACE DESIGNATED FOR THE RECEIPTOF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN <br> REJECTION OF YOUR OFFER. Ifby virtue ofthis amendment you desire to change an of r already submitted, such change may be made by telegramor letter, provided each telegramor letter makes refrence to the solicitation and this amtendment, and is received prior to the opening hour and date specified. |  |  |  |  |

12. ACCOUNTING AND APPROPRIATION DATA (If required)
13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTSORDERS IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORIT Y OF FAR 43.103(B).
C. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

X D. OTHER (Specify type of modification and authority)
UNLATERAL: FAR 52.243-2, Changes
14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Modification Control Numb
To issue a change order in accomenown JLENS Statement of Work (SOM), dated 09 March 2010, paragraph 5.4, titled Systems
Tests/Demonstrations, and JLENS System Performance Specification (MS-PRF-55628), paragraph 3.14.5.2, titled Aerostat Retrieval Cycle, for initiation of effort related to demonstration of a persistent capability for the Surveillance System (SuS).

Except as provided herein, all terms and conditions ofthe document referenced in Item9A or 10A, as heretofore changed, remains unchanged and in fall force and effect
15A. NAME AND TITLE OF SIGNER (Type or print)


## SECTION SF 30 BLOCK 14 CONTINUATION PAGE

## SUMMARY OF CHANGES

## 1. SECTION A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by $\$ 1,618,600$ from $\$ 1,814,867,002.00$ to $\$ 1,816,485,602.00$.
The following have been added by full text:

## PURPOSE

To conduct a demonstration of a persistent capability for the Surveillance System (NuS) over a fourteen (14) day period (twenty-four (24) hours/day) not later than 30 September 2011.

The purpose of the demonstration is to gather data in support of meeting the Aerostat Retrieval Cycle requirement as shown in paragraph 4, Table 1, Requirement/ Verification Cross Reference Matrix, 3.14.5.2, of the JLENS System Performance Specification (MIS-PRF-55628).

The fourteen (14) day SuS Demonstration will include continuous operation of the Platform subsystem, the Radar subsystem, and the CPG subsystem in a near-tactical configuration. The SuS Demonstration will include conducting, documenting, and analyzing (1) platform flight operations, ( 2 ) radar radiation, detection, and tracking of primary mission targets, (3) control of the SuS via the CPG, and (4) communication of radar information

SuS Demonstration objectives will be developed by Raytheon and submitted to the JLENS Product Office (JPO) for approval thirty (30) days prior to the event. SuS Demonstration "quick look" results will be submitted to the JPO every twenty-four (24) hours during the fourteen (14) day event. A final report will encapsulate results and analysis for the GuS Demonstration events and will be delivered to the JPO thirty (30) after the fourteen (14) day NuS Demonstration completes.

## 2. SECTION B - SUPPLIES OR SERVICES AND PRICES

## SUBCLIN 0017AA



The total cost of this line item has increased by $\$ 1,618,600.00$ from $\$ 1,577,118,555.00$ to
\$1,578,737,155.00.
This includes an increase in target cost o consisting of $\square$ increase in cost and a increase in facilities capital cost of money, and an increase in target fee of which $\quad$ of target cost less facilities capital cost of money.

## B-17. INCENTIVE FEE FOR SUBCLIN 0017AA/CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AACLIN 0018 are set forth below:

(Share Ratio: Government/Contractor)
Underrun: the amount by which the total allowable cost is less than the target cost until maximum fee is attained.

Overrun: $\quad$ the amount by which the total allowable cost exceeds the target cost until minimum fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:
(e) Fee Payable.
(1) The fee payable under this contract shall be the target fee increased b ents for every dollar that the total allowable cost is less than the target cost or decreased b its for every dollar that the total allowable cost exceeds the target cost. In no event shall the fee be greater thar cent of the target cost.

B-18. TARGET COST, TARGET FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017AA - (Two SDD JLENS Systems)
a. Target cost:
b. Target fee:
c. Minimum incentive fee:
d. Maximum incentive fee:
e. Total target cost and target fee:


## 3. SECTION G - CONTRACT ADMINISTRATION DATA

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c ., is revised to read as follows:

## SUBCLIN 0017AA:

(1) Amount Required for Full Funding, Including Fee:
(2) Amount Allotted Under the LOF Clause for Payment of Costs:
(3) Amount Separately Obligated for Payment of Fee:
(4) Total Amount Allotted and Obligated:
(5) Net Amount Required for Full Funding


* These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17AH)


## 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is changed as follows:

Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM
DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs $a$ a and $b$., are revised as follows:
a. General.

SubCLIN 0017 AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph $\mathrm{H}-19$ (b) applies only to the Cost Incentive and Paragraph $\mathrm{H}-19$ (c) applies only to the Schedule Incentive. The contract price amount of $\$ 1,578,737,155$ includes a target cost of (which includes $\$$ f facilities capital cost of money) and a target incentive fee of which is target cost less facilities capital cost of money.
b. Cost Incentive.
(b)(4)

(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.
c. Schedule and Performance Incentive.
(1) A maximuin
conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from with the ( $b$ ( 4 ) (b) (4) (b) (4) (4)
(a) the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007 from
(b) (4) (b) 6 )

Design review NLT' 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and carned the "Flat Zone" schedule incentive of (b) $)^{4}$ determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, from
(2) An additional performance incentive fee pool of maximum) is established and will be awarded to the contractor for meeting performance incentives associated with System Capability Reviews (SCRs) and the Developmental Test (DT)/Limited User Test (LUT) according to the schedule below:

## 002248

(a) aximum) earned based on successful conduct of technical performance defined by SCR-1.
(b) aximum) earned based on successful conduct of technical performance defined by SCR-2.
(c) aximum) earned based on successful conduct of technical performance defined by SCR-3.
(d) aximum) earned based on successful conduct of technical performance defined by LUT.
(e) The specific criteria/evidence and associated percentages related to successful completion of (a) through (d) above are defined in the Section J attachment entitled "Performance Incentive Fee Criteria/Evidence."
(f) Following completion of each milestone in (a) through (d) above, the government will determine the amount of performance incentive fee earned. If it is determined that performance incentive fee is earned, the additional contract value will be added to the total value of the contract at the time the incentive is earned.
(3) For Earned Value and cost reporting purposes, the target cost value of $\$ 1,449,378,168$ will be used.
d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.
(End of Summary of Changes)



[^0]:    7R..............
     M14 TP DTCe

[^1]:    * These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include

[^2]:    7. In consideration of the modification agreed to herein as complete equitable adjustment for the Hardware Modification proposal submitted via Raytheon letter JLENS-23414-10-140, dated 29 October 2010, the Contractor hereby releases the Government from any and all liability under this contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposal for adjustment.
[^3]:    (a) $\square$ (maximum) earned based on successful conduct of technical performance defined by SCR-1.

[^4]:    $94,288,100.52$

